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ABSTRACT OF THE DISSERTATION
Gut Reactions:
Quantitative Predictions of the Responses of Human Gut Microbiota to Medical Interventions
by
Amy Langdon
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Genetics and Genomics
Washington University in St. Louis, 2021
Professor Gautam Dantas, Chair
The collection of microbes known as the human microbiome perform vital functions for their host,
and when this community becomes unhealthy, its dysbiosis is implicated in a myriad of diseases.
The gut microbiota in particular are known to suppress colonization of opportunistic pathogens,
regulate the immune system, aid in nutrient breakdown, produce vitamins, and a growing number
of other functions. In order to intervene in a dysbiotic microbial ecology, we can try to remove
unwanted microbes or try to recolonize the gut with microbes expected to be beneficial. This
dissertation provides an overview of the state of medical interventions for the microbiome. Two
original research projects are presented detailing 1) the effects of fecal microbiome transplantation
(FMT) on the gut microbiota of adults with antibiotic-refractory Clostridioides difficile infection,
and 2) the effects of amoxicillin on the gut microbiota of children with uncomplicated severe acute
malnutrition. This is accomplished by metagenomic sequencing of the genomes of the bacteria
x

present in the stool of each patient over a study period. The bacterial community proportions,
diversity, metabolic potential, and changes over time are assessed with relation to health outcomes.
Particular attention is paid to antibiotic resistance (AR), as this represents a growing challenge and
a serious obstacle to continued therapeutic use of antibiotics to combat bacterial disease.
In the first project, we sequenced and analyzed stool samples from a Phase II clinical trial treating
U.S. adults with antimicrobial-refractory C. difficile infections by fecal microbe transplantation of
an intact microbial community from healthy donors. We expected to see that remediation of
symptoms of C. difficile infection symptoms would correlate with greater engraftment of donor
microbiota into the host, and we found this to be true. As in previous studies, we saw that the
transplant recipient adopted many individual bacterial taxa from the donor, and their eventual
microbiome composition was somewhere between the extremely dysbiotic microbiome from their
baseline samples and the healthy community from the donor. We also predicted that successful
engraftments would reduce the abundance of antimicrobial resistance genes (ARGs) in the host.
We confirmed this, and we also found a dose-response relationship between the completeness of
the adoption of the donor configuration and the reduction of ARGs in the host. Additionally, we
used selective culture to isolate 38 antimicrobial resistant organisms (AROs) from 5 different
bacterial genera and sequenced their genomes. Through tracking their identifying ribosomal 16S
sequences throughout the longitudinal study samples, we found that eradication of these strains
from the recipient microbiomes was possible and even common. These findings offer both
motivation and direction towards the development of rational and defined treatments that could
someday be used to control the carriage and spread of dangerous AROs within the gut microbiome.
The second project was a collaboration with Doctors Without Borders to evaluate the impact of
prophylactic amoxicillin on the gut microbiota of children presenting with severe acute
xi

malnutrition (SAM). Even when enrolled in nutritional therapy programs, children with SAM have
high probability of relapse and death. The fear and motivation for this randomized controlled trial
was that this broad-spectrum antimicrobial could harm the composition of the gut microbiome and
select for antimicrobial resistance. Infections with drug resistant pathogens in children who are
severely undernourished can be especially concerning. We found that the amoxicillin did indeed
have an impact on the gut microbiota with the expected rise in ARGs, but that it resolved even by
the next study visit at 4 weeks. We also investigated two mechanism behind the beneficial effects
of this prophylactic treatment on recovery from SAM. First, treatment with amoxicillin decreases
genes and microbes associated with an age-regressed malnourished community that is not adapted
to an adult diet. Secondly, study treatment reduces the incidence of diarrheal illnesses long after
cessation of antibiotics. The results of this study strongly support continued prophylactic use of
amoxicillin in children with severe acute malnutrition. Together, this body of work forwards our
understanding of how the human gut microbiota respond to perturbations and to medical
interventions in order to promote human health.
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Chapter 1
The human gut microbiome in health and disease

This chapter includes edited excerpts from the following published works:
Langdon, A.*, Crook, N.* & Dantas, G. The effects of antibiotics on the microbiome throughout
development and alternative approaches for therapeutic modulation. Genome Med 8, 39 (2016).
https://doi.org/10.1186/s13073-016-0294-z
and
Schwartz, D.J.*, Langdon, A.*. & Dantas, G. Understanding the impact of antibiotic perturbation
on the human microbiome. Genome Med 12, 82 (2020). https://doi.org/10.1186/s13073-02000782-x
and two figures from
Bulow C, Langdon A, Hink T, Wallace M, Reske KA, Patel S, Sun X, Seiler S, Jones S, Kwon
JH, Burnham CA, Dantas G, Dubberke ER. Impact of Amoxicillin-Clavulanate followed by
Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic
Potential. mSphere. 2018 Nov 21;3(6):e00588-18. doi:
https://doi.org/10.1128/mSphereDirect.00588-18
*The first two authors contributed equally to their respective articles.
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1.1 An overview of the human gut microbiome
A human being is not simply one organism with one genetic code. We depend on and sustain
millions of other organisms living in and on the human body, which are collectively known as the
human microbiome. The highest density and diversity of these microbiota is found in the
gastrointestinal tract, which is the site of interest for the research presented here. The human gut
microbiome consists of bacteria, viruses, and fungi ideally living symbiotically with their human
host, though most methods and literature (including this dissertation) focus only on the bacteria
[1]. Individual species and collective bacterial functions within the gut microbiome confer many
benefits throughout life including metabolizing dietary contributions, educating the immune
system, defending against pathogens, and contributing to overall health and optimal growth [2-6].
The gut microbiome is affected by and influences a huge number of pathologies including
inflammatory bowel disease (IBD), allergies, asthma, and neurobehavioral disorders [4, 5, 7, 8].
A key feature of the microbiome is the quantity, identity, and function of antibiotic resistance
genes (ARGs), collectively called the resistome. ARGs transmit between species within the gut
microbiome including potential pathogens. Therefore, understanding how the resistome changes
in parallel with the microbiome is vitally important [9, 10]. Accordingly, numerous avenues of
research are being pursued to understand what constitutes healthy and abnormal microbiomes and
resistomes.
The gut microbiome of an individual is both unique and dynamic. The community composition
and its diversity are affected by the age and maturity of the microbiome, diet and the environment,
and the co-morbidities of the individual. Acute external perturbation such as by medications
(especially antibiotics) can also have sweeping effects of variable duration [11-16]. However, the
2

diversity and species richness are associated with resilience in the face of perturbation. The
beneficial nature of microbial community diversity is a central dogma of the field and a recurring
theme throughout this dissertation. Figure 1.1 illustrates the variable impact of antibiotic
perturbation on diversity over time in three microbial communities with different stability, such as
might be seen in infancy, childhood, and adulthood. Although the dichotomy of stable (e.g. healthy
adult) versus dynamic (e.g. developing infant) microbiomes is likely oversimplified, it is important
to understand that the impact of an intervention/perturbation depends on the context. That is, a
relatively more stable, healthy, adult microbiome can resist and rebound faster and more
completely from the same perturbation that could change the developmental trajectory of a preterm
neonate and leave lasting changes (Figure 1.1) [17]. Partly, this difference relates to the degree of
functional diversity and redundancy in the microbiome with different strains of the same species
contributing functions or occupying various distinct and overlapping niches [18, 19].
In order to treat pathologies that are caused by a dysbiotic microbiota, we must understand how
medical interventions interact with the dynamic microbial community. After a brief discussion of
the methods by which we can observe and quantify the gut microbiome, we will discuss how the
microbiome changes throughout development and how that impacts its response to perturbation,
illustrated with specific examples from the literature. Finally, we will examine the available tools
of medical technology for intervening in dysbiosis, either by killing microbes or adding them back
in. This all serves as the context for two original research projects detailed in the following
chapters. By gaining understanding of the responses of the gut microbiota to perturbations and to
medical interventions, we can improve treatment of microbiota-linked diseases and achieve better
health for both current and future generations.
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Overarching factors: age, environment, co-morbidities

Diversity/Richness

(au)

Highest

Diet
Species/ARG diversity
Functional redundancy

Antibiotic spectrum
Antibiotic duration
Antibiotic route

Pathogen prevalance
ARGs and HGT
Beneficial microbes
(probiotics/FMT)

During

After

High

Medium

Low

Lowest
Before

Time relative to antibiotics
Figure 1.1 Antibiotic perturbation to the microbiome needs to be considered in context.
Certain factors are important to consider throughout life (overarching factors). Other factors such
as diet and the functional and species diversity and redundancy are important to consider when
the antibiotic perturbation is applied. The duration, spectrum, and route of antibiotics are vitally
important in the context of how the microbiome responds during intervention. The postantibiotic environment including availability and colonization of pathogens, MDROs, and
beneficial microbes is important to consider the resilience and response after antibiotic cessation.
These factors influence the structure and function of the microbiome before, during, and after
antibiotics throughout life. Created with BioRender.
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1.2 Methods in microbiome science and their limitations
Current microbiome research is largely concerned with “Who is there?” and “What are they
doing?” Microbiome taxonomic profiling is achieved by culture-dependent molecular or
phenotypic typing or culture-independent sequencing of taxonomically-informative marker genes
or whole metagenomic shotgun sequencing from microbiome samples, within or between
individuals [20-23]. Similarly, features and functions of the microbiome can be assessed by genelevel analysis, metabolomics, and assessment of the abundance of gene pathways for microbial
metabolic function [24-29]. These analyses are typically conducted in the context of human
development throughout life or in connection with clinical outcomes [30]. Measures of diversity
within (a) and between (b) samples can be used to compare microbial communities over time and
between disease states (extensively reviewed in [31]). Our ability to attribute disease associations
to causality is difficult and requires longitudinal, prospective studies, ideally complemented by
mechanistic validation in animals [30, 32]. However, important associations between the human
microbiome structure and function with diseases and health nevertheless provide meaningful
hypotheses and correlations [7, 30, 33, 34].
Massively parallel sequencing technologies allows quick taxonomical surveys of an entire
community by sampling genes from bacterial 16S ribosomal RNA. In addition, to assess functional
capability (i.e. abundances of metabolic pathways or resistance genes), new computational tools
can now analyze short reads from whole-metagenome shotgun sequencing, neatly sidestepping the
challenges of read assembly from a complex and uncultured community [25, 35, 36]. These
methods have been used extensively to establish baseline healthy microbiome compositions, which
can then be statistically compared to samples from patients with a disease phenotype. In addition,
5

machine learning algorithms such as Random Forests can be trained to discriminate between
samples from the healthy and dysbiotic microbiomes of individuals with a variety of health
conditions. This approach yields ranked lists of discriminatory taxa as well a model capable of
categorizing new microbiome samples as either healthy or diseased. Machine learning has been
applied to discover which “indicator” species are important to normal microbiome maturation [37],
to malnutrition [38], to protection against cholera [39], and even to colon cancer [40]. In addition
to high-throughput analysis of gene content, there has been increasing interest in the use of
metatranscriptomics [41], metaproteomics [42], and metabolomics [43] to gain additional insight
into the state of the microbiome in various disease contexts. These exciting applications underscore
the importance of an ecosystem-level view of the gut microbiota in the context of disease diagnosis
and therapeutic development.
As useful as it is, metagenomic sequencing has its downsides. Bias introduced during extraction,
amplification, sequencing, and bioinformatic processing can alter relative abundances of species
within a sample [44]. Relative abundances can range from 50-fold higher or lower than actual
depending on the specific species contribution and protocols used [44]. Complete absence of a
species may reflect bias below the limit of detection. Conversely, expansion of specific taxa may
reflect progressive and systemic bias enriching for sequencing reads from that taxa [44]. It is
therefore important to consider and correct for these biases in any experiment where taxon relative
abundance is considered using computational methods [44]. A key step in any metagenomic
sequencing experiment is to sequence similar, defined communities of different taxon proportions
to understand bias in each protocol. Sequencing defined communities can lead to computational
estimates of protocol bias that can be applied to all samples prior to analysis [44]. Furthermore,
extraction and processing can introduce contamination depending on its format and each kit has
6

its own DNA that needs to be evaluated especially when considering a potentially sterile site [4547]. Thus, it is important to use mock, negative controls of the sequencing kit only and also
contrived, defined bacterial communities to quality check metagenomic methods. Finally, the
sequences are only as good as the samples. We commonly refer to “the gut microbiome” as if it
were a singular, internally consistent community, when in fact, different microbes thrive in
different parts of the GI tract and at different proportions. The noninvasive method of collecting
stool and preparing it for sequencing is comparable across individuals, but it loses information
about microbe population distribution within the gut or the absolute abundance of the
microbes[48]. These considerations limit the type of conclusions that can be drawn from the
sequencing data.
As for antibiotic resistance genes (ARGs), the resistome is typically measured by obtaining
metagenomic sequences, as above, and annotating them with all known ARGs and variants. This
approach is of course limited to current knowledge of ARGs, and new ones appear with great
frequency. One solution to this is to use that unique property of ARGs that allows the host to
survive in otherwise lethal conditions. To more broadly characterize novel and unknown resistance
mechanisms, researchers have utilized functional metagenomics, whereby fecal DNA is cloned
into plasmids, introduced into E. coli, and plated on selective media [17, 49, 50]. These
functionally validated ARGs present in the original fecal samples encode for proteins, the majority
of which had not been previously ascribed resistance mechanisms in curated databases [50, 51]. In
the neonatal intensive care unit (NICU) where antibiotics are used and overused frequently, greater
than 40% of these ARGs derive from E. coli, Enterobacter spp., and Klebsiella spp. These ARGs
encode resistance to commonly used antibiotics in the NICU (penicillins and cephalosporins) as
well as antibiotics not used in the NICU (tetracyclines and chloramphenicol) [50]. A strength of
7

this approach is that it allows identification of a broad range of ARGs assuming expression in E.
coli. Accordingly, these novel ARGs are likely still an underestimate of the total resistome. To
date, similar methods have been unsuccessful in gram-positive bacteria. Resistance to
antimicrobials that exclusively or preferentially target gram positives such as vancomycin,
linezolid, and clindamycin would require other methods to identify.
In order to identify ARGs that are simply new variations on a family, it is possible to use existing
ARG databases to identify short conserved peptide sequences from ARG families (markers) and
use it to search metagenomic sequences from a sample of interest. This allows both strong
specificity and allows variation surrounding that markers, so it can identify novel variants. This is
how the program ShortBRED works, and it is used extensively throughout the research presented
here [25].
In summary, metagenomic sequencing is a powerful tool to probe complex and changing
communities. Used within its limitations, a great deal can be learned about the human gut
microbiome across time, individuals, and circumstances.

1.3 Microbiome development and maturation
As a child grows, the commensal microbiota develops in a predictable succession that is
generalizable across human populations [37]. The developing bacteriome, the bacterial component
of the microbiome, has been profiled many times in terms of both its taxonomy and its metabolic
functions [37, 52, 53], providing a view of the species structure over time. Less is known about
the gut-associated eukaryotes and viruses that develop along with the bacteriome, although they
form an important part of the gut ecosystem [54, 55]. The disruption of the bacterial succession
can be pathogenic in a number of ways [34, 56-58]. Infancy and early childhood in particular
contain critical developmental milestones for the microbiota as well as for the child, and it has
8

Figure 1.2 Health consequences linked to the disruption of human-associated microbiota
involving antibiotic use during development and adulthood. Red lines indicate that a single dose
of antibiotics within the time period has been linked to a health consequence, whereas a dotted red
line indicates that multiple doses of antibiotics within the time period are required to observe a
link.
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been shown that both medical intervention and lack of such intervention during this period may
have lifelong consequences for the composition and function of this ecosystem (Fig 1.2). In this
section, we discuss the instances throughout development and adulthood during which antibiotics
are often used, their effects on the microbiota, and the health and disease implications due to such
effects.

1.3.1 Birth
A child’s first contact with microbes is usually assumed to be after the rupture of the sterile
amniotic sac. However, the placenta and infants’ first stool have been found to contain a full
complement of microbes [59, 60], and a labeled strain of Enterococcus faecium has been shown
to cross the umbilical cord in mice [61, 62]; so although it appears that the first human-microbial
interaction occurs before birth, the nature of this interaction is unknown. Elucidating the function
of a prenatal microbiome is especially important because the majority of women in the United
States are prescribed antibiotics during pregnancy and delivery [63], and at least eleven types of
broad-spectrum antibiotics cross the placenta to the fetus [64]. Prior to birth, intrapartum antibiotic
administration to mothers significantly affected microbiome structure of 1 month old neonates
relative to control infants even in the absence of continued antibiotic exposure [65, 66]. Further,
intrapartum antibiotics lead to persistent enrichment of ARGs in exposed, term neonates relative
to non-treated neonates or their mothers at 6 months of life [65]. Importantly, in this study, neither
exposed nor the control children were antibiotic treated after birth. Therefore, administration of
antibiotics during this critical developmental window can lead to short- and intermediate-term
negative effects on the microbiome and resistome.

10

After birth, bacteria, viruses, and fungi colonize the gut with a subsequent rapid accumulation of
species and diversity from the mother and the environment [17, 54, 67]. Large-scale studies of the
microbiome have demonstrated that the dynamic first two years of life respond most dramatically
to antibiotic perturbation [11, 68]. Antibiotic treatment during the first 18 months of life results in
greater disruption than subsequent administration, as measured by b diversity between consecutive
samples [68, 69]. Among the most dynamic periods of microbiome development is the first 6
months of life [11, 13]. The neonatal and infant periods defined by dynamic changes in microbial
diversity on a weekly, if not daily, timescale. Dramatic strain-level changes and interactions shape
the early life microbiome providing essential metabolic and immune regulatory functions [70, 71].
This fragile developing microbial community is highly responsive to perturbations during delivery
and immediately after, so the immediate environment and events after birth are of great
consequence.
An infant’s mode of delivery is a critical determinant of their resulting gut microbial composition.
During vaginal delivery, infants are colonized by the mothers’ vaginal microflora (largely
composed of Lactobacillus, Prevotella and Sneathia species), while a Caesarean delivery omits
the vaginal microbes. Instead, the first microbes colonizing an infant delivered by Caesarean
section are of environmental origin and generally associated with the skin (such as Staphylococcus,
Corynebacterium, and Propionibacterium species) [72]. Intestinal strains of Bifidobacterium spp.
have been shown to be transmitted vertically with vaginal but not Caesarean delivery [73]. As a
confounder, antibiotics are also routinely administered perinatally during Caesarian sections,
although it is possible to delay their use until after umbilical clamping, thus separating the effect
of the mother’s antibiotic use and the infant’s. This effect is likely to further distinguish the
microbiota composition of infants delivered by Caesarian section and those delivered vaginally.
11

Postnatal antibiotics can also irreversibly disrupt the natural microbiome succession, as an infant
is unlikely to be recolonized with a second dose of vaginal microbes. The Caesarean gut
composition has been directly linked with higher susceptibility and frequency of infection by
methicillin-resistant Staphylococcus aureus (MRSA) [74], which is a symptom of instability and
low diversity in the gut ecosystem. Caesarean sections are also associated with a variety of longterm health effects, especially immunological disorders such as asthma [75] and type I diabetes
[76, 77]. Therefore, elucidating the relationships between these disorders and gut microbiome
composition is critical to understanding the risks associated with antibiotic intervention in infants.
Premature birth (birth at <37 weeks of gestation) also has a major impact on the gut microbiome,
resulting in a much greater prevalence of Proteobacteria than is usually seen in the Firmicutedominated microbiota of term infants [78]. This trend is aggravated by the routine and extensive
use of antibiotics given to premature infants in order to prevent and treat infections (Table 1) [7981]. Extended antibiotic treatment (>5 days) in premature infants is associated with a higher risk
of late-onset sepsis (primarily group B Streptoccoccus), necrotizing enterocolitis, and overall
mortality [82, 83]. Antibiotic use further shifts gut composition towards the Proteobacteria
Enterobacterales by depressing Bifidobacterium populations [84]. More generally, bacteriocidal
drugs decrease the overall diversity of the infants’ gut microbiota and select for drug-resistant
microbes [85-87].
Antibiotics delivered in the NICU are varied [88] ranging from relatively short-term exposure with
narrow spectrum agents such as ampicillin or cefazolin to long-term exposure to broad-spectrum
agents such as 3rd generation cephalosporins and carbapenems [50, 89]. The preterm gut
microbiota of NICU-hospitalized neonates is dominated by Escherichia coli, Klebsiella spp.,
Enterobacter spp., and Enterococcus spp., which are found in the NICU environment, are often
12

multi-drug resistant, and are causes of bacteremia in this population [50, 90, 91]. Antibiotic
administration in this environment results in a fundamentally altered and extremely ARG-enriched
gut microbiome acutely after antibiotics, but the response to each antibiotic differed based on
microbiome composition [50]. The overall microbiome response to gentamicin and vancomycin
could be predicted based on abundance of the species E. coli and S. aureus and the ARGs/bacterial
response regulator cpxA/cpxR [50]. Additionally, members of the Enterobacterales harbored
hundreds of novel ARGs conferring functional resistance to beta-lactams, tetracyclines, and
aminoglycosides [50]. Further research investigating strain-level diversity and functional
evolution over time in the NICU and after discharge is needed to identify the covariation and
consequences of specific antibiotic therapy in the context of birth history, diet, and environment
for each individual’s microbiome. Alternative strategies are needed to prevent and treat infections
in extremely vulnerable populations such as premature infants.

1.3.2 Early childhood
Childhood is a time of immense microbiome dynamics and environmental changes including
dietary shifts and introductions [6, 11, 92]. After vulnerable infancy, the microbiome goes through
a developmental stage (3-14 months of age) and a transitional stage (15-30 months) before
stabilizing to a near-adult like configuration [11, 74]. Bacteriophage titers start high and drop,
while eukaryotic viruses are accumulated from the environment over time [54]. Arguably, the most
significant microbiome perturbation during early childhood is the transition from breastmilk or
formula to solid foods [11, 93]. The pre-weaning microbiome is dominated by Bifidobacterium
spp. and thereafter, several microbiome states, so called ‘enterotypes’, account for the bulk of gut
community structure [11]. Microbial diversity of a breastfed child after weaning increases
commensurate with accumulation and enrichment of strains responsible for dietary metabolism
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Table 1.1 Main antibiotics used for pediatric or adult infections which modify the microbiome.
(N/A = data not available)
Antibiotic

Molecular
Target

Class

Resistance
Mechanism

Effect on gut
microbiota

Effect on
gut
transcripto
me

Effect on gut
proteome

Effect on gut
metabolome

Amoxicillin

Transpeptid
ase

B-lactam

Altered
target, Blactamase

Reduced
Enterobacteria
[96].

N/A

N/A

N/A

Ampicillin

Transpeptid
ase

B-lactam

Altered
target, Blactamase

Lower bacterial
diversity,
greater
prevalence of
Enterobacter
[85].

Increase
expression
of tRNA
biosynthesi
s,
translation,
vitamin
biosynthesi
s,
phosphate
transport,
stress
response,
proton
motive
force,
antibiotic
resistance,
and phage
[97].
Reduces
immune
cell and
mitochondr
ial gene
expression
[41].

Increased
bacterial
glycosidase
and mucinase
activity [98].

N/A

Cefotaxime

Transpeptid
ase

B-lactam (3
gen
cephalosporin
)

Altered
target

Lower bacterial
cell count [99],
Decreased
anaerobes and
Enterobacteria
[100].

N/A

N/A

N/A

rd

Chlorampheni
col

Increase
expression
of tRNA
biosynthesi
s,
translation,
vitamin
biosynthesi
s,
phosphate
transport,
stress
response,
proton
motive
force,
antibiotic
resistance,
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N/A

and phage
[97].
Ciprofloxacin

DNA gyrase

Fluoroquinol
one

Altered
target,
efflux

Decreased
Enterobacteria
[101]. Lower
bacterial
diversity [102,
103], decrease
in short-chain
fatty acid
(SCFA)
producers [104].

Increase
expression
of tRNA
biosynthesi
s,
translation,
vitamin
biosynthesi
s,
phosphate
transport,
stress
response,
proton
motive
force,
antibiotic
resistance,
and phage
[97].

N/A

N/A

Clarithromyci
n/
Metronidazole

Bacterial
50S rRNA/

Macrolide/
Nitroimidazol
e

Altered
target/ drug
inactivation

Reduction in
Actinobacteria,
partial recovery
of pre-treatment
state [105].

N/A

N/A

N/A

DNA
synthesis
Clindamycin

Bacterial
50S rRNA

Lincosamide

Altered
target

Initial decrease
of Enterococci,
Streptococci,
and anaerobic
bacteria,
subsequent
recovery of
Streptococci
and anaerobic
bacteria [106],
Reduction in
diversity of
Bacteroides
[107], decrease
in SCFA
producers [104].

N/A

Increase of
immunoglobuli
n proteins,
transthyretin,
and
chymotrypsinlike elastase
family.
Decrease in Tcell activation,
chymotrypsino
gen B,
phospholipase
A2, myosin-1a,
and
cytochrome C
[42].

Increased
creatine/creatinine,
primary bile acids,
N-acetylated amino
acids, prolinehydroxy-proline,
pyroglutamylglutam
ine, Myo-inositol,
chiroinositol,
methyl-chiroinositol, gammaglutamyl amino
acids, and host
tryptophan
metabolism.
Decreased
secondary bile
acids, enterolactone,
equol, N-acetylaspartate, short
chain fatty acids,
sugar alcohols, and
bacterial tryptophan
metabolism [108].

Erythromycin

Translation

Macrolide

Efflux

Decreases in
Streptococci,
Enterococci,
and
Enterobacteria,
increases in
Staphylococci,
and alteration in
anaerobes
[109].

Increase
expression
of tRNA
biosynthesi
s,
translation,
vitamin
biosynthesi
s,
phosphate
transport,
stress
response,
proton

N/A

N/A

15

motive
force,
antibiotic
resistance,
and phage
[97].
Gentamicin

Bacterial
30S
Ribosome

Aminoglycosi
de

Decreased
uptake,
drug
modificatio
n

Lower bacterial
diversity,
greater
prevalence of
Enterobacter
[85].

N/A

N/A

Increased
oligosaccharides
and secondary bile
acids. Decreased
short chain fatty
acids, phenolic
acids, uracil,
primary bile acids,
branched chain
amino acids, and
aromatic amino
acids [110].

Meropenem

Transpeptid
ase

Carbapenem

Altered
target, Blactamase

Reduced
Enterobacteria,
Streptococci,
Clostridia,
Bacteroides,
gram-negative
cocci [111].

N/A

N/A

N/A

Streptomycin

Bacterial
30S
Ribosome

Aminoglycosi
de

Decreased
uptake,
drug
modificatio
n

Diversity
decreases,

N/A

Increase in
peptidases,
actin
polymerization,
transthyretin,
chymotrypsinlike elastase
family,
myosin-1a, and
cytochrome C.
Decrease in
chymotrypsino
gen B and
phospholipase
A2 [42].

Bile acid
metabolism, steroid
metabolism, and
eicosanoid synthesis
affected, LTB4
decreases [112].

Ticarcillin

Transpeptid
ase

B-lactam

Altered
target, Blactamase

Lower
Enterococci
[113].

N/A

N/A

N/A

Tigecycline

Bacterial
30S
Ribosome

Tetracycline

Altered
target,
Efflux

Reduction in
Enterococci, E.
coli,
Lactobacilli,
and
Bifidobacteria,
increases in
other
Enterobacteria
and yeasts in
humans [114],
reduction in
Bacteroidetes
and increases in
Proteobacteria
[115].

N/A

N/A

N/A

Vancomycin

Peptidoglyc
an

Glycopeptide

Altered
peptidoglyc
an target

Decreased
bacterial
diversity [116].

Increase
expression
of tRNA
biosynthesi

N/A

LTB4 affected
[112]. Increased
oligosaccharides,
and decreased short-

Ruminococcac
eae and
Bacteroidacea
e increase [42].
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s,
translation,
vitamin
biosynthesi
s,
phosphate
transport,
stress
response,
proton
motive
force,
antibiotic
resistance,
and phage
[97].
Reduces
immune
cell and
mitochondr
ial gene
expression
[41].
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chain fatty acids
and uracil [117].
Low doses increase
short chain fatty
acids [118].

[11, 12, 71]. Transitions between these states accompany chronological aging, likely reflective of
differential environmental exposures including antibiotics, infections, and diet [11, 92, 94].
During childhood, microbes are continuously obtained from breast milk, other food, and the
environment [95]. When the developmental trajectory of the microbiome is altered by modifying
factors, it can negatively affect digestive function resulting in either undernutrition or obesity.
These phenotypes are often found in underdeveloped and developed countries, respectively. The
associated undesirable microbiome configurations are shaped via selection by diet (calorie
restriction or a high-calorie, low-quality diet) [119], by exposure to disease (high frequency of
diarrhea versus excessive hygiene) [120], and the use of medication such as antibacterial agents
on the microbiome [121].
Undernutrition is a devastating and widespread problem with strong links to the microbiota. It will
be discussed in detail in Chapter 3. Meanwhile, obesity has grown to epidemic proportions in
developed countries. In 2015 in the United States over 30% of adults and 17% of children were
estimated to be obese [122, 123]. The contributions of diet and lifestyle to weight gain are well
publicized, but the role of the gut microbes have only recently come to light. A high-calorie diet
shifts the microbial ecology towards Firmicutes at the expense of Bacteroidetes, thus increasing
the microbiota’s energy harvesting capacity [124]. Microbes from obesity-discordant twins can
reproduce the respective phenotypes in gnotobiotic mice [125, 126], implicating a causal role for
the microbiota in obesity. Further, antibiotic exposure during infancy increases risk of childhood
obesity in boys by age 8 [121]. Relatedly, risk of developing Type 2 diabetes increases with
repeated use of penicillins, macrolides, cephalosporins, and quinolones [127, 128]. This could be
confounded by the higher susceptibility of diabetics to infections requiring antibiotic treatment,
but this possibility is countered by the fact that anti-fungals and anti-virals, which also more
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frequently sought by diabetics, do not also increase risk of diabetes [128]. These findings support
the notion that the bacteriome has a strong but uncharacterized role in metabolic disease. Further
research is critical in order understand the mechanisms of these nutritional and metabolic health
effects.
Antibiotic administration during childhood typically consists of short courses of relatively narrow
spectrum agents for respiratory tract and oropharyngeal infections [129]. Intermittent postnatal
antibiotic exposure was associated with decreased abundance of Clostridiales and Ruminococcus
even though the overall number of species and diversity was similar between exposed and
unexposed groups after 1 year of life [94]. However, if antibiotics are frequent or in the context of
underlying gastrointestinal disturbances or inadequate diet, their effects can be magnified [94,
130]. Specifically, short courses of antibiotics were shown to exacerbate dysbiosis from Crohn’s
disease [130]. Thus, antibiotics, diet, and environment acutely impact the developmental trajectory
and diversity of the gut microbiome of the developing child. Rational and frugal antibiotic use is
warranted to prevent microbiome disruption and inform the restoration of the microbiota after
antibiotic use.

1.3.3 Adulthood
The mature adult microbiome has been assessed across many populations. The largest project to
date is the Human Microbiome Project, which assessed 15-18 body sites in 242 participants in
2012 and continues to sample new individuals [131]. An important finding from this project was
that microbial populations differ significantly among healthy individuals, and so far there is no
single composition that is defined as healthy, aside from a preponderance of Bacteroidetes and
Firmicutes.
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The overall diversity and community architecture of healthy adult microbiomes does not change
dramatically in the absence of significant perturbation [11, 132, 133]. However, among healthy
adults, the relative abundance of specific taxa can change on a daily or weekly scale [134], but
microbial functions are more stable longitudinally [135]. As an important caveat, some of these
inferred differences regarding daily changes may be an erroneous result of sequencing error from
various sources and amplification of or depletion of rare and low abundance taxa [44, 136]. Biases
can be both taxa-intrinsic as well as protocol specific [44]. For example, among 3 different
extraction protocols, the relative abundance of C. difficile was universally lower and F. nucleatum
higher than the actual abundance of the mock community [44]. Conversely, certain protocols
enriched for specific taxa over others in all mock communities. The range of individual abundances
among replicates varied as much as 10-fold within a given extraction and processing protocol [44].
Therefore, a daily change in relative abundance could be a result of systematic bias and should be
evaluated as such.
On a much larger scale of populations throughout time, trends observed in Human Microbiome
Project follow-up studies include a decrease in microbiome diversity in developed countries as
compared to those of hunter-gatherers or societies with restricted access to Western medicine [137,
138]. This is often attributed to the hygiene hypothesis, which in addition to improved cleanliness
points to the overuse of antibiotics during infections as causal to a reduced microbiome diversity
in developed countries. A large range of antibiotics have indeed been shown to transiently or
permanently alter the composition of healthy adult microbiotas, usually via depletion of one or
several taxa (Table 1). Importantly, the effects of an antibiotic on an in vivo microbial community
likely depend on the community state, and are not neccesarily predictable based on in vitro
susceptibilities of isolated members of the community. These predictions are complicated by the
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widely varying physiological concentration of the drug, different growth stages [139], antibioticassociated bacteriophage induction, interdependence among microbial taxa, and ‘cheaters’, or
susceptible microbes protected by other microbes’ extracellular resistance enzymes [140].
Repeated empirical measurements of the effects of an antibiotic on a microbial community are
therefore the best way to predict how a particular gut microbiome will respond to a given antibiotic.
Oral amoxicillin exposure caused significant shifts in microbiome composition for approximately
30 days on average and for over 2 months for some subjects [141]. Significant shifts were also
reported during an oral course of ciprofloxacin which persisted for several weeks, and these shifts
were partially restored to an extent that was highly subject-dependent [102, 103]. A similar
subject-dependence in post-antibiotic trajectory was also observed during exposure to cefprozil
[137]. The effect of antibiotics also differs by body site, where the throat and saliva were found to
recover their initial diversity after antibiotics much more quickly than the gut [104, 105]. In
addition to their effect on the phylogenetic makeup of the microbiome, antibiotics select for
resistance in the surviving gut microbiota via increased expression of antibiotic resistance, stress
response, and phage genes [97] (Table 1.2), as well as increased abundance in the resistance genes
themselves [107, 142]. These mobilized resistance genes serve as a reservoir for drug resistance
in pathogens [143].
These effects of antibiotic exposure on the microbiome architecture are thought to play an
important role in the resulting health status of the host, either in immunological disorders [75, 144]
or in susceptibility to pathogens [74, 120, 145, 146] (Table 1.2). Indeed, antibiotics have been
shown to alter both the transcriptome and proteome of host tissues [41, 42]. In particular, it has
been shown that perturbation of the host proteome follows a different timescale than perturbation
of microbiome species content, with the streptomycin-altered proteome recovering before the
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Table 1.2 Examples of antibiotic-induced changes in microbiota leading to disease
Feature

Effect of antibiotics

Pathological Consequence

Antibiotic resistance Enrichment for resistance genes and resistant Multiple drug resistant tuberculosis; carbapenem-resistant E. coli
organisms [142]. In some cases, it can increase infection [148].
rates of genetic exchange between microbes
[147].
Vitamin production Depletion of vitamin-producing bacteria.

Broad-spectrum antibiotic use (especially beta-lactams with Nmethylthiotetrazole moiety) can cause vitamin K deficiency leading to
hypoprothrombinemia and uncontrolled bleeding [149].

Digestion

Changes proportions of relevant metabolic
functions in the microbiome [150].

By altering the efficiency of nutrient extraction from food, this can
contribute to obesity [119, 126].

Diversity

Reduces number of different microbes [102].

Lower diversity reduces ecological stability and resistance to pathogens.
Increased susceptibility to infection and diarrhea [74, 120, 145, 146].

Resilience

Lowers availability of microbes to take over
newly open niches.

Each course of antibiotic acts on a new ecology. Recovery to a stable state
and to which particular stable state is highly individual [137].

Immune regulation

Increases inappropriate immune activity.

Asthma, allergies, and autoimmune diabetes have all been linked to
antibiotic use [57, 128, 151].

Composition

Varying effects across taxa and for different
durations.

See Table 1. [84, 97, 102, 103, 141]
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microbiota, while the clindamycin-perturbed proteome remained perturbed after microbiota
recovery [42]. In an elegant study by Morgun, et. al., the effect of antibiotics on the host
transcriptome were classified by their major cause; the reduction of bacteria in general caused a
decrease in immune cell expression, whereas the presence of antibiotics and a prevalence of
antibiotic-resistant bacteria together caused a reduction in both mitochondrial gene expression and
the number of mitochondria per cell. Although the ability of antibiotics to affect mitochondria (due
to their bacterial origin) had been known before, the authors uncovered the virulence pathways of
P. aeruginosa as a significant driver of mitochondrial gene loss and host cell death in this study
[41]. It is clear that antibiotics, both alone and through their effects on the gut microbiota, have
significant effects on host gene expression. The majority of studies investigating the effects of
antibiotics on the gut metabolome focus on susceptibility to infection, most notably C. difficile and
S. typhimurium. C. difficile-associated deaths top 14,000 per year [148]. Infected patients receive
high-dose, extended duration treatment with multiple antibiotics, yet nevertheless up to 65% of
patients relapse. Recurrence of C. difficile-associated diarrhea is associated with a low-diversity
microbiome [145]. Both clindamycin and tigecycline exposure decrease diversity with a
corresponding increased susceptibility to C. difficile [115, 146]; similarly, streptomycin and
vancomycin use have been shown to cause an increased susceptibility to S. typhimurium infection
[120]. As a potential mechanism for this effect, it has been shown that antibiotic treatment with
streptomycin or clindamycin results in the release of sugars and bile acids due to the depletion of
key metabolic activities encoded in gut commensals [152, 153]. These liberated nutrients thus
provide an ecological niche which can be exploited by pathogens. Indeed, multiple studies in
which high-throughput metabolomics was performed on an antibiotic-treated microbiome have
shown that high concentrations of antibiotics reduce or eliminate most products of bacterial
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metabolism (including short-chain fatty acids and secondary bile acids), with a corresponding
buildup of their precursors (including oligosaccharides, sugar alcohols, and primary bile acids)
[43, 108, 110, 117, 154]. In addition, compounds throughout bile acid, steroid, and tryptophan
metabolism were significantly altered by antibiotic treatment [112, 155] (Table 1.1). These
metabolic effects appear to be independent of antibiotic class, and rather depend on antibiotic
concentration, as it has been shown that subtherapeutic doses of penicillin, vancomycin, penicillin
+ vancomycin, or chlortetracycline actually increase short-chain fatty acid concentration [118].
These effects collectively provide multiple metabolic routes for C. difficile to exploit following
antibiotic treatment. In particular, antibiotics have been shown to deplete the bile acidhydroxylating activity of C. scindens, which is required for protection against C. difficile infection
[156]. As an additional mechanism promoting infection, antibiotics may enhance bacterial
translocation out of the gut [157]. Thus, it is clear that provision of broad-spectrum antibiotics may
be counterproductive in the treatment of these recalcitrant, often antibiotic-resistant infections. In
contrast, antibiotic alternatives such as fecal microbiota transplants (FMTs), discussed below, have
been used to treat C. difficile with upwards of a 90% cure rate [158].
Assuming that the healthy adult microbiome is completely stable is inaccurate as high temporal
resolution studies have shown variability of different body sites over time [136]. However,
individuals with the greatest Shannon diversity in the gut microbiome had the smallest temporal
variability with most taxa stable over long periods of time in the absence of perturbation [133,
136]. These findings have ushered in one of the central dogmas of the microbiome field:
microbiomes with higher diversity are more resilient to perturbation. For instance, researchers
treated 12 men with 4-days of a cocktail of broad-spectrum antibiotics (meropenem, gentamicin,
and vancomycin) and sequenced their gut microbiome over a 6-month period [159] (Table 1).
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Immediately after treatment, Klebsiella spp., Enterococcus spp., and E. coli increased in
abundance, but by 8 days after treatment, no significant differences were observed in these species,
suggesting acute bacterial blooms are short-lived after cessation of antibiotics in this population.
Microbial richness and diversity dramatically decreased, but Shannon diversity progressively
recovered in the subsequent 6 months. Although at the gross community level, the microbiome
was restored, the absolute number of species remained significantly lower from baseline samples
[159].
The relatively stable adult microbiome requires more sensitive measurement techniques to assess
long-term perturbations. Once the microbiome has stabilized around age 2-3 [11, 37], minimal
differences in microbiome stability have been observed between bi-monthly samples in children
treated with various oral antibiotics [68]. Furthermore, researchers treated 66 healthy adults with
one of four oral antibiotics and collected salivary and fecal samples 1, 2, 4, and 12 months after
exposure [160]. Although both the fecal and salivary microbiome was acutely disrupted by
antibiotics as measured by Bray-Curtis dissimilarity, no differences persisted at 1 year suggesting
long-term stability and resilience to perturbation. An alternative explanation, however, is that the
microbiome is meta-stable, and antibiotic perturbation may transition the structure to an
alternative, yet still stable (meta-stable) composition with similar numbers of species and diversity.
Indeed, modeling existing datasets of healthy humans treated with antibiotics supports this
assertion [159-161].
The response to the same antibiotic appears individualized at the taxa level likely reflective of
underlying comorbidities, local environment, or prior antibiotic history commensurate with ARG
abundance (Figure 1.1) [102, 103]. Additionally, the microbiome is temporally variable in relative
abundance even in the absence of perturbation, but these changes were small compared to the
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impact of ciprofloxacin [103]. Specifically, members of the Clostridiales, among the most
abundant pre-ciprofloxacin taxa, were absent in all samples after treatment [102]. Advanced
sequencing techniques combined with longitudinal sampling will continue to refine our
understanding of the long-term consequences and changes to the microbiome from antibiotic and
environmental perturbation.
Lumping together all antibiotics is an oversimplification as antibiotic spectrum clearly impacts the
response of the gut microbiome [162]. Indeed, computational modeling of the short-term impact
of various antibiotics demonstrates that ciprofloxacin, a broad-spectrum fluoroquinolone
antibiotic, showed more displacement from microbiome equilibrium than amoxicillin, a narrow
spectrum b-lactam antibiotic [161]. Certain strains of the same species do not recover, suggesting
potentially lasting consequences. Similarly, oral cefprozil (a β-lactam antibiotic) altered strain
level dynamics shifting the dominant strain within each individual [163, 164]. It is likely that some
of the individualization of antibiotic effects on strain-level diversification is due to copy number
variation or expression of specific ARGs [164]. Although certain ARGs were significantly
increased immediately after antibiotic treatment, reports of lasting ARG changes vary per study
likely reflective of the microbiome composition, spectrum and route of antibiotic administration,
comorbidities, and other factors (Figure 1.1) [159, 163, 164]. However, if a stable microbiome is
challenged simultaneously by changing the environment such as foreign travel to high infectious
burden areas or intensive care admission and antibiotic treatment, the acute microbiome effects
can be more dramatic [165-167]. These results demonstrate the myriad acute changes to the
microbiome and suggest the remarkable plasticity of the stable adult microbiome to routine
perturbation.
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Although the adult microbiome is relatively stable in healthy adults, the microbiome dynamically
changes during acute inflammation of gastrointestinal illness such as IBD [7]. In one study
researchers characterized samples as dysbiotic by computing Bray-Curtis dissimilarity between all
samples to a reference set of non-IBD controls. Any samples that scored above the 90th percentile
from the median sample-sample difference from the reference set were termed dysbiotic. Using a
multi-omics approach, they identified that 24% of samples from patients with Crohn’s disease
were dysbiotic both metagenomically and metabolomically, far above the expected 10% threshold.
Similarly, during dysbiotic shifts, patients had discursions from expected constitution not only of
metagenomes and their associated metatranscriptomes and metabolomes, but also in
measurements of inflammation [7]. Both concurrent and antibiotic use in the prior 6 months
correlated with gut dysbiosis further exacerbating the inter-individual and intra-individual
microbiome compositional differences [130, 168]. Thus, acute, antibiotic perturbations to the
microbiome have greater effect on community structure when the microbiome is dynamically
changing due to inflammation.
Another potentially more dynamic time of microbiome structure is in the elderly. Indeed, small
studies have shown decreased microbiome diversity in the elderly including decreased Firmicutes
and increased Proteobacteria, similar to the neonatal microbiome [169-171]. In contrast to younger
adults, the microbiome was more variable in its composition when sampled within 3-month
intervals [171]. One potential explanation for this finding is the number and diversity of nonantibiotic medications that have been shown to impact the microbiome [16]. More research needs
to be conducted on the elderly microbiome in the context of immune senescence, co-morbidities,
and infection susceptibility, but the stability of the human microbiome may decrease at either
extreme of age.
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1.4 Medical interventions for the gut microbiome
1.4.1 Antibiotics
The widespread use of antibiotics in the past 80 years has saved millions of human lives, facilitated
technological progress, and killed incalculable numbers of microbes, both pathogenic and
commensal. Human-associated microbes perform an array of important functions, and we are now
just beginning to understand the ways in which antibiotics have reshaped their ecology and
affected those functions, sometimes to our health but often to our detriment.
How the microbiome responds to antibiotics is affected by the state of the microbiome at the time
of perturbation (diet, species, and functional diversity and redundancy) and the strength of the
perturbation (route, spectrum, and duration of antibiotics). After cessation of antibiotics, the
prevalence of beneficial or potentially pathogenic and/or antibiotic resistant (AR) microbes that
recolonize the gut microbiome governs the initial and long-term outcomes of antibiotic treatment.
These factors must be considered individually and collectively when correlating changes in
microbiome structure and function to human health and disease.

Long-term effects of antibiotic perturbation depend on microbiome state
Understanding the long-term effects of specific antibiotics is vital to limiting the negative
consequences of AR development and international spread. Despite the overall stable community
structure over time, changes in species composition may persist even after short antibiotic
perturbations to the stable microbiome [103, 159, 163]. The immediate environment of an
antibiotic recipient is an important source of newly introduced microbes [17, 48, 50, 91, 172, 173].
This simple fact deserves a great deal more attention to ensure reliable, positive long-term
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outcomes from perturbations of the gut microbiome. Longer term effects are also highly dependent
on stage of life and stability of the microbiome (Figure 1.1) [11, 13, 17, 68, 174, 175].
Frequent antibiotic use in the NICU delays preterm neonatal microbiome maturation initially, but
the microbiota recovers to a similar taxonomic composition to antibiotic naïve term controls by 15
months of life [17]. Similar microbiome recovery at four years of life has been shown for antibiotic
treatment in the first year of life [92]. Thus, even in periods of extreme microbiome turnover, from
a gross, structural level, the microbiome is still resilient and converges to a similar architecture
with antibiotic naïve infants. Although the overall composition of the microbiome was similar,
specific species and ARGs present up to two years later distinguished them from healthy controls
[17] (Table 1.1). Specifically, multi-drug resistant organism (MDRO) Enterobacterales (E. coli,
Klebsiella spp., and Enterobacter spp.) acquired in the NICU persisted in the gut microbiome up
to 1 year after NICU discharge with greater than 99.997% identity between them. Machine learning
algorithms classified fecal samples post-NICU discharge deriving from an antibiotic naïve or
frequently exposed infant with 96% accuracy [17]. Among the most significant features
distinguishing these samples were ARGs including class A β-lactamases as well as functionally
validated ARGs to piperacillin and tetracycline and members of the order Clostridiales.
In addition to allowing MDR potential pathogens to maintain a foothold within the GI tract,
frequent antibiotic exposure in this critical microbiome developmental period diminished strain
diversity, enriched for ARGs, and conferred a less stable composition [13]. Researchers collected
monthly stool samples from 39 children from 2 months to 3 years variant in their antibiotic usage
[13] (Table 1). Twenty of these children received between 9 to 15 antibiotic courses mainly for
otitis media and respiratory infections. They found that antibiotic-naïve children harbored
increased strain-level diversity of Bacteroides fragilis, a key commensal important for immune
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education and bacterial tolerance [13, 176]. Harboring more strains of the same species is believed
to be a component of a resilient microbiome as well as providing different functions [71, 177, 178].
It is likely possible to achieve microbiome health and resilience to perturbation either by increased
strain level diversity within a species or by maintenance of a diverse array of different species. In
both instances, this taxonomic diversity leads to functional diversity. Intriguingly, the authors also
speculated that frequent antibiotic courses could lead to multiple colonization attempts by
beneficial species (e.g. Eubacterium rectale) in lieu of initial colonization and in vivo evolution.
That is, because of frequent antibiotic administration, beneficial microbes are not surviving and
undergoing in vivo adaptation, potentially inhibiting the microbiome plasticity expected of a
healthy, interconnected, adult microbiome [13, 179]. Consecutive samples from the same
individual on antibiotics were less similar to each other than antibiotic naïve children. This result
is not surprising as antibiotics are expected to acutely diminish diversity. However, these children
also exhibited dramatically higher variance in this measurement even when not directly treated
with antibiotics. ARGs also increased during antibiotic treatment, not all of which returned to
baseline after antibiotic cessation (Table 1) [13]. Frequent antibiotic courses during childhood can
thus lead to long-term consequences such as increased microbiome variability, decreased strainlevel diversity, and increased MDR potential pathogens. Thus, although the overall taxonomic
structure recovers, specific entities remain in the pediatric microbiome as evidence of prior
antibiotic exposure.

Collateral harm from the use of antibiotics
It is difficult to overstate the beneficial impact that control of bacterial pathogens has had on our
current standard of living. However, our control over microbial disease is diminishing. Due to
heavy selective pressure from widespread antibiotics use, human pathogens have repeatedly
30

acquired the genetic capacity to survive antibiotic treatment. Antibiotic-resistant (AR) infections
are precipitously rising, while at the same time the discovery of new antibiotics is slowing, such
that withdrawals of antibiotics from healthcare exceed approvals by a factor of 2:1 [180]. In 2019,
it is estimated that there were 2.8 million AR infections and 35,000 deaths from them in the US
alone [181]. By 2050, the toll is projected to rise to 10 million deaths annually worldwide [182].
These figures suggest we are reaching the end of the antibiotic era.
In addition to the development of resistance, it is becoming increasingly apparent that the ecology
of the human microbiome (i.e. the collection of cells, genes, and metabolites comprising the
bacteria, eukaryotes, and viruses which inhabit the human body) is fundamentally disrupted by the
use of antibiotics. A dysbiotic microbiome may not perform its myriad and vital functions such as
nutrient supply, vitamin production, and protection from pathogens [183]. Dysbiosis of the
microbiome has indeed been associated with a large number of health problems and causally
implicated in metabolic, immunological and developmental disorders as well as susceptibility to
infectious diseases [34, 56-58, 130, 151, 184, 185]. The broad nature of these diseases provides
ample cause for concern over the unintentional consequences of antibiotic use.

1.4.2 Alternative approaches for modulating the gut microbiota: targeting
pathogens while maintaining the healthy microbiota
It is clear from the examples highlighted above that overuse of antibiotics can often have negative
effects on host phenotype through collateral damage to commensal microbes. As an alternative to
broad-spectrum drugs, there has been increasing interest in the development of narrow-spectrum
treatments which specifically reduce the capacity of pathogens to cause disease, while leaving
commensals unharmed. The enormous variety of anti-virulence strategies are briefly mentioned
here. For a more complete discussion of anti-virulence therapeutics, please see [186-189].
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Anti-quorum sensing
Quorum sensing (QS) is the mechanism by which bacteria coordinate behavior as a function of
population density. The concentration of a continuously secreted signaling molecule serves as a
marker for local population size, and virulence programs are up- or downregulated as a function
of this concentration [190]. QS plays a critical role in the virulence of many pathogens including
V. cholerae and P. aeruginosa [191]. Quorum sensing can be inhibited in a variety of ways,
including 1) destruction of the quorum-sensing signal [192], 2) accelerating turnover of key QS
proteins [193-195], and 3) competing with the quorum-sensing signal for binding to key regulatory
proteins [196-198]. However, P. aeruginosa variants resistant to such quorum-quenching drugs
have been recently identified [199, 200], and it has been proposed that the development of this
resistance was caused by a benefit to quorum sensing machinery outside the context of a clinical
infection [201]. Such results indicate a risk for developing an anthropocentric view of “virulence”
pathways and highlight a need for holistic understanding of their roles within the cell in order to
develop robust anti-virulence strategies.

Anti-toxin production
Toxin production is critical to the virulence of a wide variety of species. As countermeasures to
toxin activity, small molecule inhibitors of C. difficile major virulence factor toxin B [202], B.
anthracis lethal factor [203], B. anthracis protective antigen channel [204], and E. coli verotoxin
[205] have been identified. Taking inspiration from the body’s own defense repertoire and the
historical use of antisera against bacterial infections [206], antibodies against shiga [207, 208] and
anthrax [209] toxins have also been developed. Small-molecule inhibitors of ToxT, the
transcription factor controlling the production of cholera toxin, have been shown to be effective in
mouse models, though prone to resistance development [210, 211]. Lastly, inhibitors of type 2,
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[212], type 3 [212-218] and type 4 [219] secretion systems have been identified, collectively
inhibiting the virulence of Y. pseudotuberculosis, C. pneumoniae, C. trachomatis, S. flexneri, S.
typhimurium, E. coli, and Brucella sp. It is unclear whether inhibition of toxin production is a
stable strategy against virulence, because although toxin producers are at an increased metabolic
burden relative to nonproducers when the toxin is ineffective, this environment provides a strong
selective pressure for anti-toxin-resistant mutants or even for mutants which overexpress the toxin
[201].

Other anti-virulence strategies
There are several alternative strategies to combat virulence. In particular, pilus formation is critical
to the adherence of uropathogenic E. coli to host cell tissue, and several compounds which inhibit
pili (pilicides) have been effective against this strain [220-223]. As carotenoid production is
important to the mitigation of host reactive oxygen species by S. aureus, it has also been found
that inhibitors of carotenoid production reduce the virulence of this organism [224]. The
production of biofilms is important to the virulence of several pathogens and also interferes with
the delivery of antibiotics to their target site. For this reason, anti-biofilm compounds, in addition
to restricting virulence on their own [225], represent a critical added component to broad-spectrum
antibiotics or to orthogonal anti-virulence therapies. Lastly, siderophores facilitate the scavenging
of rare iron from the host environment and are therefore critical to the survival of several pathogens
including P. aeruginosa. It has been proposed that compounds which inactivate siderophores
represent an evolutionarily robust anti-virulence strategy [226]. Taken together, anti-virulence
therapies represent a promising alternative to traditional broad-spectrum drugs through the
reduction of potential off-target effects as well as the reduction in the number of organisms under
pressure to develop resistance, even if the ideal “evolution-proof” therapy is not found.
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1.5 Restoring or enhancing the microbiota
Antibiotics affect microbiome and resistome composition, with the degree of perturbation
determined by many factors (Figure 1.1) [13, 48, 94]. Ultimately, if an individual’s microbiome is
distorted beyond correction after antibiotic cessation and treatment of an underlying condition,
microbiome repair can be considered [172, 227-231]. In contrast to approaches focused on
targeting certain members of the gut microbiota, a growing strategy to prevent enteric infections
is through the delivery of additional or replacement species to the gut to increase its resilience to
infection. These strategies include the use of probiotics, fecal microbiota transplants, and phage
therapy.

1.5.1 Probiotics
Probiotics are defined as “live microorganisms which when administered in adequate amounts
confer a health beneﬁt on the host” [232]. Probiotics are often seen as an approach to restore or
improve a dysbiotic microbiota [233], and are an effective treatment for a wide range of
gastrointestinal diseases including C. difficile infection [234], antibiotic-associated diarrhea [235237], and acute infectious diarrhea [238]. Lactobacillus species are used as probiotics [239], with
L. salivarius effective against Listeria infection [240] and L. reuteri preventive against antibioticassociated diarrhea [241]. In addition, B. animalis has been shown to protect against infections in
infants [242] and E. coli Nissle, in addition to being an effective treatment for crohn’s disease and
inflammatory bowel disease [243], has been shown to reduce enteric counts of multi-drug-resistant
E. coli [244]. Most meta-analyses of probiotic use agree that while probiotics can be effective
against a range of gut dysbioses, more specific data are needed on which probiotics are best for
particular patient groups, especially in light of extensive inter-individual variation in gut
microbiota composition.
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With the increasing ease of genetic engineering, there is a growing interest in augmenting the gut
microbiota with engineered strains to expand gut function or resilience beyond what can be
conferred by unmodified strains. Recently, engineered L. lactis has been used to express and
deliver antimicrobial peptides against E. faecium, reducing pathogen counts by 10,000-fold in vitro
[245]. Excitingly, a recombinant invasive strain of L. lactis was used to transfect host cells with
engineered DNA in vivo, stimulating host production of tuberculosis antigen in mice [246].
Additionally, “sense and destroy” probiotics, which encode sensors for biomarkers of pathogenic
strains, have been recently developed. Upon detection of a pathogen, these probiotics activate a
genetic program to kill their target. Two recent studies harness the detection of 3-acyl-homoserine
lactone (used in QS) to specifically target Pseudomonas aeruginosa. Pathogen killing is mediated
by expression of engineered antimicrobial peptides in one instance [247] and by increased motility,
biofilm degradation enzymes, and antimicrobial peptides in the second [248]. Such “smart”
therapeutics promise to reduce the development of resistance and off-target effects by localizing
treatment to strains of interest in time and space. However, production of killing compounds is not
the only mechanism by which engineered probiotics can ward off infections. Increased
understanding of resource utilization within the gut is enabling the development of strains which
can outcompete pathogens at colonization of available metabolic niches [152, 249]. Although
significant challenges regarding the safety, containment, and consumer acceptance of engineered
probiotics remain to be fully addressed, the therapeutic potential enabled by genetic engineering
of the gut microbiome is enormous.

1.5.2 Fecal microbiota transplants (FMTs)
For opportunistic, antibiotic–resistant infections such as Clostridium difficile, alternative therapies
to antibiotics are superior to antibiotics [250, 251]. The transfer of fecal microbes from a healthy
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person to a patient has been used as a remedy for recurrent diarrhea for at least 1700 years [252].
It is in its essence the most comprehensive and crude form of probiotic therapy, administering an
entire balanced community at once, without necessarily knowing which components are valuable.
The stool transplantation can be done either from the same individual before disruption (auto) or
from a healthy donor (allo). FMTs are introduced orally or via enema. The most common diseases
for which this has been trialed are Clostridiodes difficile infection (CDI) and steroid nonresponsive colitis [228, 230, 253]. More recent research has investigated whether FMT can more
generally be applied to reduce ARG and MDRO burden of resistance-rich microbiomes [254-257].
Multiple case reports have described successful decolonization of MDRO Klebsiella spp.,
Pseudomonas, and vancomycin-resistant enterococci with allo-FMT (reviewed in [256]), though
no placebo-controlled trials have yet been conducted for this express purpose. Autologous FMT
has been proposed as a mechanism to restore a pre-antibiotic microbiome baseline after disruption
[48, 231, 258], and indeed it may have helped recovery for 10 patients after the ARG expansion
caused by amoxicillin-clavulanic acid (Figs 1.3-1.4). Similarly, probiotics, strains of beneficial
bacteria consumed during or after intervention, are thought to mitigate some of the negative
consequences of antibiotics on the microbiome [237, 259, 260]. Recently, however, probiotics,
autologous FMT, and spontaneous recovery were evaluated for their impact on microbiome
recovery after antibiotics in healthy volunteers [48].

Twenty-one subjects had their stool

microbiome sampled, then they were treated with 7 days of ciprofloxacin and metronidazole and
randomized to twice daily probiotics for 1-month, autologous FMT from a pre-antibiotic baseline
sample, or no treatment. Antibiotics disrupted gut microbiome richness and diversity and
metabolic pathways devoted to sugar, carbon, and amino acid metabolism [48]. Auto-FMT
immediately after antibiotics rapidly corrected this dysbiosis with no difference in Bray-Curtis
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Figure 1.3 Enrichment of resistance genes by mechanism was determined by comparing
normalized counts (RPKM) post-Amox-Clav to enrollment. Beta-lactamases (black) were most
enriched and formed a majority of the antibiotic inactivation enzymes enriched. Efflux pumps
were also enriched, and functional metagenomic selections suggest co-occurrence of betalactamases and efflux pumps on a mobile element.
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Figure 1.4 Beta-lactamase genes were significantly enriched after Amox-Clav (two-tailed t test, P
0.0017). Participants randomized to autoFMT (red) and saline (gray) both returned to baseline by
day 90. Participant numbers are noted at the beginning and end of each line.
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dissimilarity from baseline 1 day after FMT. Spontaneous microbiome recovery occurred 21 days
after antibiotic cessation. Surprisingly, probiotic administration (a commercially-available 11
species consortium called Bio-25 [261]) delayed and prevented microbiome structural and
functional recovery with significant compositional differences present 5 months after antibiotic
cessation. Increased relative abundance of Enterococcus casseliflavus and Blautia producta
correlated with maintained low species richness [48]. An important caveat to this study is that the
probiotic was administered after antibiotics in lieu of during treatment which is common in clinical
practice [237]. This probiotic has also not been evaluated for its prevention of antibiotic-associated
diarrhea, and unless the probiotic species are resistant to the administered antibiotics, it likely
would be eradicated during antibiotic treatment. Thus, autologous FMT accelerated and probiotic
administration prevented microbiome recovery after antibiotic administration. Although probiotic
administration is common practice, these data suggest this practice may exacerbate microbiome
recovery and requires further study.
Despite the benefits of FMT detailed above, introduction of fecal microbes into another individual
is not without risk. Recently, two immunocompromised patients became bacteremic with ESBL
producing E. coli derived from donor FMT, one of whom succumbed to the infection [262].
Accordingly, the FDA has decreed that all investigational FMT products be screened specifically
for MDRO, excluding individuals at higher risk for MDRO colonization and rejecting donor stools
that contain MDRO [263]. One other intriguing point shown in recent FMT studies is that during
the dynamic period of engraftment, new strains, species, and ARGs appear that were not detectable
in either the donor or the recipient [172, 230]. The frequency and reproducibility of this effect
shows that the post-treatment environment remains a major factor in the ultimate composition of
the gut microbiome (Figure 1.1). The sheer number of recent metagenomically sequenced FMT
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studies with publicly available data make this phenomenon an excellent candidate for a metaanalysis. Accordingly, the fate of the microbiome after antibiotic perturbation depends on the
environment, resilience, and availability of microbes in the post-disruption period including FMT
or probiotics.
In the near term, FMTs have the potential to be a critical tool to limit the spread of AR and lengthen
the time to obsolescence for remaining viable antibiotics. In the future, FMTs may be replaced by
defined preparations of their therapeutic factors as detailed knowledge of the ecology of the gut
microbiota increases.

1.5.3 Phage therapy
In addition to the bacterial inhabitants of the gut, there exists an equally fascinating viral
community exerting a profound effect on the gut microbiota, and in turn the host. As the natural
predators of bacteria, bacteriophages (phage) were used to treat bacterial infections before the
advent of antibiotics, after which the use of phage therapy was restricted to the USSR [264]. As
antibiotics have become less effective, phage have received significant renewed therapeutic
interest, as phage are often highly specific to their target bacteria (reducing off-target effects on
the rest of the microbiota) and self-replicating (reducing production costs relative to small
molecules and enabling co-evolution with a pathogen target). Indeed, phage active against E.
faecalis biofilms [265], B. cereus [266], and P. aeruginosa [267] have been recently identified,
among many others. As is the case for antibiotics, the development of resistance is evolutionarily
favorable, but it has been observed for some bacteria/phage combinations that phage-resistant
mutants are less virulent [268, 269]. Excitingly, phage have also been the subject of genetic
engineering to improve their function modulating the gut ecosystem [270]. In particular, the
expression of a biofilm-degrading enzyme on the genome of T7 phage enabled the reduction of
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biofilm concomitantly with cell lysis in a positive-feedback manner [271]. T7 has also been
engineered to encode quorum-quenching enzymes as a defense against biofilm formation [272].
Recently, the natural transformation capacity of bacteriophages has been coupled with
programmable nucleases to enable the generation of phage which specifically kill bacteria with
undesirable genomic sequences, such as antibiotic resistance genes or virulence factors [273, 274].
By programming sequences from resistance genes and lytic phage as substrates for nucleases,
Yosef, et. al. [275] generated a system providing a selective pressure for loss of antibiotic
resistance. Based on these reports, we envision that the first diseases for which phage therapy
would be appropriate are those whose bacterial cause is well-defined, refractory to antibiotics, and
accessible to phages, such as M. tuberculosis, V. cholerae, C. difficile, enteroaggregative E. coli,
and diffusely-adherent E. coli. Although significant hurdles involving resistance to both phage and
engineered nucleases need to be cleared, it is clear that phage, both natural and engineered, hold
great promise as tools in the fight against pathogens and dysbiotic community states in the future.

1.6 Preview
The overview of this chapter is meant to provide context for following the two original research
projects. One uses antibiotics as a medical intervention, while the other introduced new beneficial
microbes through allogeneic FMT. One examines the effects of perturbation on a fragile lowdiversity microbial ecosystem in early childhood; the other is an adult community that has been
shaped by many courses of antibiotics without eliminating the problem. Their responses to
perturbation are different in many respects, yet with many of the same actors and the same goals.
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Chapter 2
Restoration and reduction of antibiotic resistance in the gut
microbiota of patients with recurrent Clostridioides difficile

This chapter includes the full text edited from the following accepted manuscript:
Langdon A*, Schwartz DJ*, Bulow C, Sun X, Hink T, Reske KA, Jones C, Burnham CD,
Dubberke ER, Dantas G. Microbiota Restoration Reduces Antibiotic Resistant Bacteria Gut
Colonization in Patients with Recurrent Clostridioides difficile Infection from the Open-Label
PUNCH CD Study. Accepted manuscript at Genome Medicine (2021).
*The first two authors contributed equally to their respective articles.
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2.1 Abstract
Once antibiotic resistant bacteria become established within the gut microbiota, they can cause
infections in the host and be transmitted to other people and the environment. Currently there are
no effective modalities for decreasing or preventing colonization by antibiotic resistant bacteria.
Intestinal microbiota restoration can prevent Clostridioides difficile infection (CDI) recurrences.
Another potential application of microbiota restoration is suppression of non-C. difficile multidrug
resistant bacteria and overall decrease in the abundance of antibiotic resistance genes (the
resistome) within the gut microbiota. This study characterizes the effects of RBX2660, a
microbiota-based investigational therapeutic, on the composition and abundance of the gut
microbiota and resistome, as well as multidrug resistant organism carriage, after delivery to
patients suffering from recurrent CDI.
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An open-label, multi-center clinical trial in 11 centers in the United States for the safety and
efficacy of RBX2660 on recurrent CDI was conducted. Fecal specimens from 29 of these subjects
with recurrent CDI who received either one (N=16) or two doses of RBX2660 (N=13) were
analyzed secondarily. Stool samples were collected prior to and at intervals up to 6 months post
therapy and analyzed in three ways: 1) 16S rRNA gene sequencing for microbiota taxonomic
composition; 2) whole metagenome shotgun sequencing for functional pathways and antibiotic
resistome content, and 3) selective and differential bacterial culturing followed by isolate genome
sequencing to longitudinally track multidrug resistant organisms.
Successful prevention of CDI recurrence with RBX2660 correlated with taxonomic convergence
of patient microbiota to the donor microbiota as measured by weighted UniFrac distance.
RBX2660 dramatically reduced the abundance of antibiotic resistant Enterobacteriaceae in the two
months after administration. Fecal antibiotic resistance gene carriage decreased in direct
relationship to the degree to which donor microbiota engrafted.
Microbiota-based therapeutics reduce resistance gene abundance and resistant organisms in the
recipient gut microbiome. This approach could potentially reduce risk of infections caused by
resistant organisms within the patient and the transfer of resistance genes or pathogens to others.

2.3 Background
Antibiotic resistant (AR) infections account for billions of dollars in healthcare costs and tens of
thousands of deaths every year in the United States alone [276]. Infections caused by antibiotic
resistant organisms (AROs) are even more devastating because of dwindling therapeutic options.
Increasing global usage of antibiotics raises the abundance and prevalence of antibiotic resistance
genes (ARGs) and AROs both within an individual and the environment [277-280]. Even when
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appropriately delivered, antibiotics disrupt the commensal gut microbiota, select for antibiotic
resistance, and decrease colonization resistance to AROs and opportunistic pathogens [174, 281,
282]. Therefore, development and implementation of antibiotic-sparing alternatives is imperative
to limit the sequelae of increased AR worldwide.
Antibiotic treatment increases the risk of Clostridioides difficile infection (CDI) by decreasing
colonization resistance mediated by commensal organisms [283, 284]. Currently, CDI is primarily
treated with orally bioavailable antibiotics such as vancomycin or metronidazole, which further
contributes to microbiome disruption, AR infections, and risk for recurrent CDI [285-287].
Furthermore, antibiotic treatment with metronidazole and vancomycin increases the carriage of
AROs such as vancomycin-resistant Enterococci (VRE) [87]. Increased gastrointestinal carriage
of VRE in the context of C. difficile colitis can predispose patients to VRE bacteremia with 2.5fold increased mortality relative to vancomycin-sensitive Enterococci [288, 289]. Thus,
development of antibiotic-sparing treatments to restore gut microbiota composition, enhance
colonization resistance, and limit increasing antibiotic resistance is warranted.
Fecal microbiota transplantation (FMT) is a technique whereby donor stool from healthy
individuals is delivered into the gastrointestinal tract of a recipient patient. FMT is rapidly gaining
recognition as a mostly safe and highly effective treatment for preventing recurrent CDI [287, 290,
291], and analogous investigational microbiota-based therapeutics are under evaluation in
controlled clinical trials [292, 293]. Additionally, these approaches have the potential to restore
other aspects of a disrupted gut microbiome [48]. Indeed, previous studies have demonstrated
taxonomic changes to the gut microbiota via 16S rRNA gene sequencing after FMT for recurrent
CDI commensurate with an increase in gut microbial diversity, a marker of microbiota health [286,
287]. While some patients respond well to a single FMT, some require repeat FMTs to prevent
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CDI recurrence, and it is accordingly important to be able to predict engraftment success [172]. It
was recently shown that probability of bacterial species engraftment after FMT was related to the
taxonomic abundance of each species in the donor and in the recipient [172]. Some studies also
suggest that there may be a reduction in carriage of ARGs and selected AROs such as VRE after
FMT [255, 294]. It is therefore theoretically possible to utilize FMT or similar investigational
treatments with a high abundance of non-resistant species to displace AROs from the recipient’s
microbiome. Accordingly, we sought to investigate the abundance of AROs and ARGs in patients
treated with RBX2660—a microbiota-based investigational therapeutic for alleviation of recurrent
CDI.
RBX2660, a liquid suspension of donor microbiota screened for bacterial, viral, and parasitic
pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant
Enterococci (VRE), and extended-spectrum ß lactamase (ESBL) expressing Enterobacteriaceae
has recently been deployed to treat recurrent CDI [228, 295]. Here we examine the effects of this
treatment on the recipient’s microbiome, ARG prevalence within the gut, and the fates of patientderived ARO isolates over the course of a 12-week Phase II clinical trial, and up to 180 days post
therapy. We found that patients who adopt a more donor-like microbiota composition, determined
by weighted UniFrac distance seven days after RBX2660, were more likely to be CDI recurrencefree during the 180-day observation period. We tracked ARO abundance in the recipient’s stool
after initial therapy via longitudinal strain tracking of amplicon sequence variants (ASVs) based
on the 16S rRNA gene sequences of cultured isolates. We utilized whole metagenome shotgun
sequencing and ARG prediction using ShortBRED to quantify ARGs in the recipient, which we
find is correlated with weighted UniFrac distance from the donor. Taken together these data show
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that in addition to CDI treatment, RBX2660, and potentially FMT in general, can be used to reduce
overall ARG abundance and ARO carriage in a recipient’s microbiome.

2.4 Methods
2.4.1 Trial design
Fecal samples in this study were derived from a Phase 2 prospective open-label cohort study
administering the microbiota-based restoration therapeutic RBX2660 to patients with recurrent
CDI (NCT01925417). Safety and efficacy analysis of this trial has been published [228], and the
study protocol is detailed there and reproduced here (Fig. S1). The first patient was enrolled August
15, 2013 and the last was enrolled December 16, 2013. Forty patients were recruited at 11 study
sites within the United States. For inclusion, patients 18 years or older had at least two rounds of
standard-of-care oral antibiotic therapy with at least two recurrences or hospitalizations for CDI.
They also had to take or start oral antibiotics for CDI symptoms including at least 7 days of oral
vancomycin. Exclusion criteria included medical diagnoses and procedures that could rationally
impact the gut microbiome including uncontrolled diarrhea after CDI treatment, concurrent
antibiotic therapy for an illness other than CDI, or history of inflammatory bowel disease, irritable
bowel syndrome, chronic diarrhea, or celiac disease [228]. Patients with compromised immune
systems including steroid use, neutropenia, chemotherapy, or a life expectancy less than 12 months
were also excluded. The primary outcome was incidence of serious adverse events through 56 days
after the last treatment. Secondary outcomes included incidence of serious adverse events 6 months
after the last treatment, absence of CDI 56 days after last dose, quality of life score, and
hospitalization data after RBX2660. Prior to administration of the study drug, all patients were
given at least 7 days of oral vancomycin (125mg four times per day) followed by RBX2660 via
47

enema from one of 21 samples from four healthy donors. Of the 34 patients that passed screening,
29 succeeded in submitting longitudinal fecal samples suitable for microbiome analysis. If a
patient had a recurrence of CDI symptoms, they were offered a second dose of RBX2660. The
study population was 97% white, 67.6% female, and had a mean age of 68 years [228].

2.4.2 Study drug
The microbiota-based restoration therapeutic RBX2660 is a 50g/150mL suspension of donor stool
containing at least 107 CFU live microbes in polyethylene glycol 3350/0.9% sodium chloride USP
solution. The donor stools were screened extensively for MRSA and VRE as well as viral,
bacterial, and parasitic enteric pathogens as previously described [228]. Aliquots of all 21
RBX2660 products from 4 donors were retained and utilized for this study.

2.4.3 Sample collection
Stool samples were collected at day 0 (after finishing vancomycin treatment and before RBX2660
administration), and at days 7, 30, 60, 90, and 180 post treatment, though many patients did not
provide all samples (Fig. 2.1). Samples were collected at home by patients and immediately
shipped on ice (4 °C) in dedicated sterile, airtight containers via FedEx. The stool samples were
divided into 500mg aliquots that were placed at -80 °C immediately upon receipt by Rebiotix, Inc.
Samples were shipped from Rebiotix, Inc. on dry ice (-20 °C) to Washington University in St.
Louis, Missouri.

2.4.4 DNA extraction and sequencing
Fecal DNA was extracted from 0.25g of stool via phenol-chloroform extraction as follows. Stool
was combined with 250uL of 0.1mm zirconium beads, 500uL of 200mM NaCl / 200mM Tris /
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Figure 2.1 Sampling schematic. Patients were given an FMT with RBX2660 (green square) after
vancomycin oral therapy (left panel). Stools (labeled as maroon circles) provided were sequenced
and used for subsequent analyses. If a patient had CDI recurrence (red triangle), they were offered
a second dose of RBX2660 (green square) with subsequent stools provided after second study drug
(right panel). Any antibiotic treatment during the trial is labelled as yellow diamonds. Patient IDs
colored red failed first treatment and received antibiotics or second dose and constitute the RI
group (n = 17). Patients who had no recurrence of symptoms or received antibiotics were
considered successes (SI group, n = 12). All subsequent figures utilize data after first dose. Data
after second RBX2660 is used only for Figures 2.5A-E and 6D. Three stool samples that failed
sequencing were excluded from this Figure and downstream analyses.
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20mM EDTA solution, 210uL of 20% SDS buffer, and 500uL 24:25:1 phenol:chloroform:IAA
(pH 7.9) while on ice. This mixture was homogenized via bead beating for 4 minutes, then
centrifuged at 4 °C for 3 minutes at 6800rcf. The aqueous supernatant was transferred to pre-spun
lock-phase PLG columns (5Prime, #2302820), an equivalent volume of phenol:chloroform:IAA
was added, and the tube was inverted and then centrifuged at max speed (20,800 rcf) for 5 minutes.
The aqueous phase was transferred to a clean tube with 600 uL of cold isopropanol and 60 uL of
3M NaOAc (pH 5.5), mixed, and incubated at -20 °C overnight. The resultant precipitate was
pelleted by centrifugation at 20,800 rcf at 4 °C for 20 minutes. The supernatant was decanted, and
the pellet was washed by adding 500 uL of 100% EtOH at 25 °C, centrifuging at 20,800 rcf at 4 °C
for 3 minutes. The ethanol was pipetted off, and the pellet was air-dried for 15 minutes in dark,
sterile conditions. Finally, the pellet was resuspended in 50uL of TE buffer (Ambien #9861) while
incubating at 30 °C for at 5 to 15 minutes. The resulting DNA was processed with QIAQuick PCR
purification column (QIAGEN #28106) with 4uL of 100mg/mL RNase added to 300uL of Buffer
PB at step 1 and incubated with the resuspended DNA for 2 minutes at room temperature.
The 16S rRNA gene was amplified from fecal DNA as follows: 1.5 ng of fecal DNA was used as
template for PCR reactions using 5PRIME HotMasterMix (Quantabio #22000401) with universal
16S rRNA gene primers 515F (5’-GTGCCAGCMGCCGCGGTAA) and 806R (5'GGACTACHVHHHTWTCTAAT). An 8bp barcode unique to each sample was designated, and
each reaction was run in triplicate with a negative (no template) control. The amplicons were run
on a 1% TAE agarose gel with SYBRsafe DNA stain and gel-purified with Qiagen Gel Purification
Kit (#28115). Eluted amplicons were quantified with PicoGreen dsDNA (ThermoFisher #P7581),
pooled, and purified with Agencourt AMPure XP bead purification protocol per the manufacturer’s
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instructions (Beckman Coulter #A63881). The pool was loaded at 8pM concentration with 25%
PhiX and sequenced on the Illumina MiSeq platform with 2 x 150 bp paired end reads.
For whole metagenome shotgun sequencing, 130 uL containing at least 500 ng of genomic DNA
was sonicated (Covaris E220 model) into 500-600bp fragments at 4 °C for 75 seconds, at intensity
4, duty cycle 10%, and 200 cycles per burst. Fragmented DNA was concentrated into 63 uL volume
using the QIAQuick PCR Purification kit (Qiagen). End repair was performed using 0.5 uL of
three enzymes: T4 ligase (NEB #M0203S), Taq polymerase (NEB #M0267S), and T4 PNK (NEB
#M0201S), with 1 uL of 1mM dNTPs and 2.5 uL of T4 buffer with 10mM ATP (NEB #B0202S).
The end-repaired genomic fragments were barcoded by incubating the DNA mixture with 0.8 μl
of T4 DNA ligase and a unique sequencing barcode at 25 °C for 10 min. Samples were then pooled
by column of the 96-well plate, purified by QiaQuick PCR purification kit, and eluted in 15 uL of
EB. Gel purification was similar to 16S rRNA gene sequencing but for all fragments from 400900 bp in length, and final elution volume was 12 uL. Finally, 2uL of each of the shotgun fragment
pools was amplified using 1 uL of 10 uM Illumina nonspecific primers using 2X Phusion HF
Master Mix and water up to 25uL total reaction volume with the following cycling conditions: 17x
for 30s each of 98 °C , 65 °C, and 72 °C with a 5 minute 72 °C final extension and hold at 4 °C.
The product was then quantified by QuBit and pooled at equal concentrations. Purified libraries
were then prepared for sequencing on the Illumina HiSeq platform with paired end reads of 2 x
150bp. Metagenomic shotgun sequencing samples were re-sequenced if the associated barcodes
appeared in fewer than 1M reads [296]. Samples that failed sequencing were excluded from
analysis and removed from Figure 2.1.

2.4.5 Isolation and genomic analysis of AROs
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In order to determine the fates of specific AR bacterial strains, each fecal sample was plated on
selective and differential media as described below. Frozen samples were thawed once before
DNA extraction in order to aliquot 1mL for culture. Stool was incubated for 2 hours in Tryptic
Soy Broth at 35 °C, and two drops of the stool/broth mixture were streaked onto each of the
following plates: Sheep’s Blood Agar (SBA), (BD 22161), VRE ChromeID (Biomerieux 43851),
MacConkey with Cefotaxime (Hardy G121), CHROME ESBL (Hardy G321), Hardy Cetrimide
Agar (Hardy G18), and MRSA Spectra Agar (Remel 01822). An incubator with 5% CO2
atmosphere was used for SBA, while the rest were incubated at standard atmospheric compositions
and grown at 37 °C. For each selective plate, 4 colonies were chosen for isolation. These colonies
were subcultured to an SBA plate and labeled A-D. Each colony was determined to the genus or
species level by VITEK MALDI-TOF MS (KB v3.2.0), then subjected to antimicrobial
susceptibility testing where it was categorized according to clearance zone diameter cutoffs from
CLSI 2016 guidelines [297]. All isolates were stored in -80 °C in Tryptic Soy Broth with 10%
glycerol.
The Qiagen Bacteremia kit was used to extract genomic DNA from 0.25g bacterial mass
from pure culture using the manufacturers’ instructions. Shotgun sequencing was performed as
above with each isolate at 100X coverage of the estimated genome size. Genomes were assembled
with spades v3.10 (kmer sizes 21,33,55, and 77 on careful mode) and quality controlled with
QUAST v4.5 [298]. ARGs from isolate genomes were annotated using Resfinder 4.0 [299]. Core
genes were extracted with Prokka v1.12 [300], then aligned and compared using Roary v3.12.0
[301]. Phylogenetic trees were generated from core binary genes using RaxML v8.2.11 [302] with
the GTR Gamma model with name derived from DADA2 ASV (see next section). A phylogenetic
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tree was constructed using Methanobrevibacter as an outgroup, then trimmed to show closely
related outgroups per genus displayed. Visualization was done with the ggtree package in R.

2.4.6 Isolate tracking in fecal samples using ASVs
The 16S rRNA gene from the isolate shotgun genomes was assembled with PhyloFlash v3.3 with
bbmap option [303] and then aligned to the Silva 16S rRNA gene database release 132 (clustering
NR99). From the now full-length 16S rRNA gene sequence assembled from each isolate[304], the
in silico amplicon from the respective universal 16S rRNA primer was obtained via mothur v1.37.5
[305]. Each of these isolate-derived amplicons was then formatted for inclusion as a pure sample
in DADA2 v1.8. The matching ASV was then quantified within patient samples throughout the
study.

2.4.7 Resistance gene prediction and quantification
ShortBRED protein markers were built from the Comprehensive Antibiotic Resistance Database
(CARD) 3.0 (02/2019 update) database using shortbred-identify.py with cluster identity 90% and
screened against Uniref90 (02/2019 update) [25]. The number of hits for each gene was determined
with ShortBRED-quantify, which normalizes reads based on marker length and read depth. A
gaussian linear mixed effects model created using the glmer function of the lmer4 package in R
was used to predict ARG totals based on the distance from donor (DFD) metric. The formula for
the full model was ARGs ~ DFD + (1 | PatientID), and the fixed effect DFD was restricted to 1 for
the null model. In the response variable ARGs, the data was log transformed using glmer option
gaussian (link= “log”) to normalize the right-skewed distribution. For visualization, the y axis of
ARG totals was expressed as log (ARGS+1) which avoids infinite values. An ANOVA with chisq
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test comparing the full and null models was run to determine the value of DFD in predicting ARG
totals in a metagenome (Chisq= 72.28, d.f.(full)=1, p<2.2x10-16).
ARGs were categorized according to mechanism and then by gene family as available in the
CARD 3.0 ontology. Gene families present in at least 10% of samples from either day 0 or day
180 were assessed by the Kruskal-Wallis rank sum test for differences between day 0, day 180,
and associated donor samples. The gene families with significant differences by Kruskal-Wallis
then underwent pairwise comparison with Wilcoxon rank sum tests with Benjamini-Hochberg
correction.

2.4.8 Taxonomy and microbial functional pathway prediction
The annotation of 16S rRNA gene sequences was performed with DADA2 v1.8 with a lower limit
read cutoff of 1M reads [21]. Taxonomy was inferred using intrinsic IdTaxa from DADA2 as well
as DADA2’s internal call to DECIPHER v.2.6.0 [306]. Further processing of 16S rRNA gene
sequencing data was performed using Phyloseq [307]. Shotgun metagenomic sequences were
demultiplexed, trimmed and filtered using Trimmomatic v0.33 [308] with the following
parameters: leading and trailing sequences of 10bp, with a sliding window between 4 and 20bp,
and minimum length of 60bp. Deconseq v0.4.3 on hsref38 was used to screen out any human DNA
[45]. MetaPhlAn v2.0 [20] was then used to predict taxonomy down to the level of species.
Functional pathways of the gut microbiome were inferred using HUMAnN2 by mapping
unassembled sequencing reads to functionally annotated pangenomes [26]. The package prcomp
v3.5.3 was used to calculate and plot the principal component analysis (PCA) of both the
taxonomic and functional profiling, which were scaled during graphing (Fig. 2.2). The package
ggbiplot was used to draw vectors corresponding to the contributions of the main taxa
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differentiating the ‘single intervention’ (SI), ‘repeat intervention’ (RI), and donor groups. A
DPCOA plot with Euclidean distances was also generated through phyloseq.

2.5 Results
2.5.1 Taxonomic and functional pathway composition converge to a donor-like
conformation after successful therapy
A multi-center trial of RBX2660 for recurrent CDI was conducted in 2013. Forty individuals were
consented, and 31 patients completed the 6-month trial (Fig. S1) [228]. Two patients had
insufficient sampling frequency and were therefore excluded from our analysis leaving 29
individuals whose time courses of CDI symptoms, RBX2660 administration, and antibiotic receipt
are shown in Figure 2.1. 12 patients did not experience a CDI recurrence after a single dose of the
study drug (single intervention or SI group) while 17 experienced a recurrence between day 7 and
day 60. The 17 patients with recurrent CDI received a repeat intervention with antibiotics and/or
repeat RBX2660 (RI group; Fig. 2.1 Patient ID red text; median 15 days post initial RBX2660).
Participants who received a second dose of RBX2660 were not necessarily pre-treated with
antibiotics before as per study protocol (Fig. S1) [228]. We first longitudinally determined the
taxonomic composition of the gut microbiota after the first dose of RBX2660 [296] (Fig. 2.1, left
panel) using 16S rRNA gene sequencing analyzed via DADA2 [21], and computed weighted
UniFrac distance from donor (DFD), which serves as a metric of engraftment [309]. After the first
study treatment, the microbiota DFD shows a decreasing trend over time after treatment indicative
of increased similarity with donor microbiota composition, but this differed by eventual treatment
outcome (Fig. 2.2A). At time 0, there was no difference in median DFD between patients who
responded to a single dose (SI) and those who received a repeat intervention (RI) for recurrent CDI
55

(p>0.05, Mann-Whitney U test). However, at day 7 after the first study treatment, microbiota DFD
was significantly higher for individuals who eventually received repeat intervention after day 7 for
recurrent CDI (Fig. 2.2B, median 0.31 vs. 0.22, Mann- Whitney U test, p<0.05). The adoption of
similar microbiota profiles to the donors by day 7 after the first study treatment is therefore
significantly predictive of engraftment success of the initial therapy during the observation period.
Although distance from donor appears to decrease for the RI group at day 60 (Fig. 2.2A), this
observation is only based on the 4/17 individuals yet to experience CDI recurrence. These data
demonstrate that in successful first treatments, the overall patient microbiota profile shifts quickly
to resemble the donors after the study treatment. However, convergence is never absolute for these
patients during the length of the study, with a mean DFD of 0.179 at 180 days after the first study
treatment (Fig. 2.2A). This degree of engraftment is consistent with what has been reported
previously for FMTs in the literature [172, 310]. We further investigated the impact of the
microbiota-derived restoration therapy on the patient fecal microbiota using whole metagenomic
shotgun sequencing with both taxonomic and functional profiling [296]. Each of the four donors
contributed 2-8 samples for a total of 21 individual donor
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Figure 2.2 Microbiota composition similarity to donor at seven days is predictive of
treatment outcome. The donor and recipient microbiota compositions were assessed via 16S
rRNA gene sequencing followed by DADA2 and their similarity to the donor product was
quantified by weighted UniFrac at each timepoint. A). Gray lines represent individuals
successfully treated with one administration (SI group) while red lines are patients who needed
further treatment (RI group, a second product or antibiotics). N = 28 patients and 130 samples. B)
Plot demonstrating average distance from donor at timepoints 0 and 7d after treatment. N= 28 total
patients and 44 samples. Box subsumes 75% of the data with horizontal bar at the median. *,
p<0.05, Mann-Whitney U test.
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samples (Fig. S2). The donor microbiota was dominated by Firmicutes, which is expected in
healthy US adults [311], whereas the recipient microbiota prior to RBX2660 had increased
abundance of Proteobacteria, which is a hallmark of antibiotic-disrupted microbiota [312, 313]
(Fig. S2). To explore this data, principlecomponent analysis was performed. The PCAs in Fig.
2.3A and 2.3B were visualized for successful engraftments only (SI group), which revealed
distinct microbiota communities between the donors and recipients at day 0 (as notated by
nonoverlapping 95% confidence ellipses; Fig. 2.3A), but not thereafter. We next determined
microbiome-wide functional pathways for the SI group as inferred using HUMAnN2 [26] (Fig.
2.3B). Similar to taxonomic composition, PCA of the diverse functional pathways found in these
patients with successful treatments were significantly different (nonoverlapping 95% confidence
ellipses; Fig. 2.3B) from those of the healthy donors only at the baseline timepoint. We also
utilized Linear Discriminant Analysis with LEfSe to identify discriminatory features at 7 days
indicative of receiving further intervention [314] (Fig. S3). This analysis identified microbial
pathways for membrane and biosynthetic processes were enriched in responders after the first
dose. Individuals requiring re-intervention (RI group) had microbial functions enriched for
flagella, pathogenesis, and ion binding. For a clearer picture of the changing trajectories over
time, each of the HUMAnN2 pathways was plotted separately with each of the day 0 and day 7
pairs (Fig. S4). These have been grouped by direction of change after treatment (i.e. whether a
particular treatment group was enriched or depleted for a specific pathway after treatment). It is
thus possible that certain microbial functions are restored after initial treatment (Fig. S4), but
patients still suffer CDI recurrence. Therefore, likelihood of successful treatment by RBX2660 is
correlated with taxonomic and functional convergence to a more donor-like conformation.
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2.5.2 Key taxa discriminate those patients who require repeat intervention
To identify the specific microbial taxa correlated with treatment outcome, we utilized PCA to
visualize differences in 16S rRNA gene-based taxonomic composition, as inferred by DADA2,
between recipient day 7 samples stratified by eventual outcome as well as donor samples for
comparison (Fig. 2.3C). The output from DADA2 is amplicon sequence variants (ASVs), which
may differ by as few as 1 nucleotide, and have been shown to improve specificity and sensitivity
of organism identification [21, 315, 316]. The ASVs were numbered in order of overall prevalence
within all samples for clarity. At day 7, patients who subsequently received a repeat intervention
of either antibiotics or repeat RBX2660 therapy, the RI group, showed a significantly different
taxonomic composition compared to either the SI group (Adonis, p=0.028) or the donors (Adonis,
p=0.001) (Fig. 2.3C). The taxa identified by PCA driving the difference between the centroid
positions included 25 ASVs above 5% importance and 11 above 10% importance (Fig. 2.3D). The
taxonomy-labelled vectors influence the samples on Fig. 2.3C away from the origin in the direction
indicated, so vectors pointing in the direction of the centroid of the donor represent important
donor taxa, vectors in the direction of the SI group identify important features of success after
initial therapy, and vectors pointing towards the centroid of the RI group identify features
correlated with requiring additional treatment. In this PCA analysis of taxa at 7 days, the genera
Blautia and Roseburia were most representative of the donors and success after initial therapy (SI),
and ASVs representing members of the genera Escherichia/Shigella, Klebsiella, and Pluralibacter
were most associated with likelihood of requiring repeat intervention (Fig. 2.3D). Three separate
ASVs from the Akkermansia genus provided a large portion of the variation, and in some severely
perturbed samples at day 0 and 7, A. muciniphila ASV 2 exceeded 40% of the entire microbial
composition (Fig. S5). After day 30, however, A. muciniphila ASV 2 often maintained a stable
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Figure 2.3. Taxonomy and microbial functional pathways converge after therapy receipt. AB) Principal component analysis (PCA) of patient microbiome taxonomic composition from 16S
data (A) and of functional pathway abundances from whole metagenomic sequencing (B) in the
SI group. Each colored dot represents an individual fecal sample after the first intervention with
circle representing 95% confidence interval with non-intersecting circles therefore statistically
significant. Panel A shows 96 samples from all twelve patients with successful treatment and all
four donors, while Panel B shows 52 samples from eight successful patients and four donors (all
of those who passed shotgun sequencing quality filters). C) PCA from timepoint 7 samples after
first study treatment only, colored by SI or RI group (46 samples from all donors and all patients
with Day 7 samples; patient N=25; donor N=4). Each sample is connected to the centroid of its
outcome group by a segment of the same color. D) taxonomy biplot shows the vectors of influence
from taxa in distinguishing day 7 samples. The input samples, axes, and origin are the same as in
C.
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abundance of < 25% in the SI group, while abundance in the RI group was highly variable after
re-intervention (Fig. S5B). Replication of the PCA through phyloseq’s dpcoa function again
showed Akkermansia contributing variation but not correlating with treatment outcome (Fig. S6).
Of note, C. difficile was not among the top indicators. Its corresponding ASV as well as C. difficile
toxin genes, detected through custom ShortBRED markers (Fig. S7A), were <2% relative
abundance in any sample and did not correlate with treatment outcome (Fig. S7B). Based on the
findings from our PCA analysis, we temporally characterized the relative abundance of these 11
most discriminatory ASVs over time after the first treatment for the SI group (Fig. 2.4). For
subjects who did not have CDI recurrence (the SI group), donor ASVs including Roseburia ASV7,
Blautia ASVs 1 and 3, and Anaerostipes ASV8 were notably absent in day 0 specimens (Fig. 2.4).
By day 7, these taxa increased in relative abundance, and by the end of the trial at day 180, their
abundance was similar to the donor microbiome. Conversely, ASVs corresponding to
Enterobacteriaceae, Escherichia, Akkermansia, and Klebsiella were abundant at time 0 for the
recipients with their abundance declining over time. Thus, the taxa associated with a successful
first RBX2660 treatment (Fig. 2.3D) begin to change relative abundance at 7 days after first dose
with continued adoption of a more donor-like conformation over the subsequent 180 days. At 30
days after first study drug, 14/17 of the RI group had already suffered a CDI recurrence and
received either a second FMT or antibiotics (Fig. 2.1). Thus, we cannot investigate whether the
relative abundance differences at timepoints later than 7 days would also be associated with
success. However, given the trends in relative abundance changes, it is likely that further adoption
of a donor-like conformation would also be associated with success (Fig. 2.4). We have identified
several taxa at 7 days after RBX2660 (Fig. 2.3D) whose presence and relative abundance changes
during the first 180 days are associated with limiting CDI recurrence.
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2.5.3 Microbiota restoration concomitantly reduces antibiotic resistant
organisms and antibiotic resistance genes.
Antibiotic resistance in the donor and recipient’s gut communities at any time was detected both
by selective and differential culture and by annotation of ARGs from metagenomic shotgun
sequencing data and assembled whole genome sequences of cultured isolates[304]. Selective and
differential culture yielded 38 ARO isolates (5 Enterobacter, 3 E. coli, 3 Citrobacter, 2
Pluralibacter, 19 Enterococcus faecium, and 6 Enterococcus faecalis) identified by matrix assisted
laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) and confirmed via
genomic analysis [296](Additional file 2). Antibiotic susceptibility profiles (Fig. 2.5A-E) revealed
resistance to 9 of 13 tested antibiotics across 5 genera, as measured by disk diffusion assay. A
phylogenetic tree of all isolates was then created to demonstrate evolutionary relatedness and
pruned to show each displayed isolate with the most closely related publicly available sequences.
Enterobacter (Fig. 2.5A), Escherichia (Fig. 2.5B), Citrobacter (Fig. 2.5C), and Pluralibacter
(Fig. 2.5D) demonstrated phenotypic resistance to amoxicillin as well as 1st and 3rd generation
cephalosporins. Multiple E. coli isolates additionally demonstrated resistance to gentamicin,
doxycycline, and chloramphenicol (Fig. 2.5B). Importantly, given recent safety concerns
regarding bacteremia caused by ESBL E. coli after FMT [262], we identified E. coli in a donor
resistant to amoxicillin, cefazolin, and ceftriaxone indicative of ESBL production (Fig. 2.5B).
Fortunately, neither patient receiving this product experienced an invasive infection from E. coli
[228]. We also identified VR Enterococcus faecalis and Enterococcus faecium present in 8
patients throughout the course of the study (Fig. 2.5E). Annotation of the 41 assembled genomes
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with known ARGs through Resfinder detected 350 resistance genes predicting resistance to all
major classes of antibiotics (Table S3).
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Figure 2.4 Taxa significantly associated with distance from donor and successful response to
RBX2660. A heatmap demonstrating the relative abundance over time after first RBX2660 is
shown for donors and the SI group. These taxa are the top 11 identified by the PCA in Figure 3D
as significantly associated with successful treatment. Dark blue corresponds to 0.001 percent
relative abundance with lighter blue 0.1% relative abundance. Each column represents a sample
from a patient over time from left to right with donor samples at the right. N = 109 samples from
12 subjects from SI group and 4 donors.
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While the objective of this study was not to find or evaluate causal genotypes explaining empirical
resistance, the AROs generally followed these rules: isolates with resistance to amoxicillin and
cephalosporin antibiotics were typically associated with bla genes while dfra1, aac / aadA1, and
floR corresponded to trimethoprim-sulfamethoxazole resistance, gentamicin resistance, and
chloramphenicol resistance respectively (Table S3). There was no resistance to meropenem
observed, and the single isolate with ciprofloxacin resistance did not have a known genomic
marker associated. The cohort in this study harbored a substantial burden of ARGs and AROs, and
we sought to track these species longitudinally via deeper metagenomic sampling.
The species corresponding to the 38 isolated AROs are common causes of healthcare associated
infection, are often multi-drug resistant, and can participate in horizontal gene transfer between
commensals and other pathogens within the gut and environment [317-319]. Because sequencing
has the potential to be more sensitive at fecal detection of these organisms than bacterial culture
[320], we sought to track these species within samples within our cohort. Accordingly, the ASVs
associated with each ARO isolate that we identified were mapped by reconstructing rRNA genes
in sequenced isolates, conducting in silico PCR to obtain 16S rRNA gene sequences, and
annotating them with DADA2 (Fig. 2.5). ASVs corresponding to each cultured ARO (Fig. 2.5AE) were tracked over time after first study drug (Fig. 2.5F-J). The relative abundance of the ASVs
plotted in Fig. 2.5F-J represent multiple related strains with identical 16S rRNA sequences, which
demonstrably contain all of the cultured AROs but can also represent susceptible sub-populations.
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Figure 2.5. Antibiotic resistant organisms cultured from patient and donor stools and the
corresponding ASVs from species were tracked over time. A-E) Antibiotic susceptibility
profiles for each cultured organism from any sample from donor and patient with the
corresponding phylogenetic tree. All breakpoints in antibiotic concentration were determined by
CLSI 2016 criteria. Taxonomic labels are derived from DADA2 ASV assignments, with
Enterobacter being further specified from family level based on metaphlan2 and MALDI-TOF
taxonomy assignments. The designation A indicates recipient and D indicates donor. The
following number indicates study ID number followed by timepoint of isolation. A and E
connote single colonies on separate plates. F-J) Each of the ASVs corresponding to the species in
A-E are shown in relative abundance over time in 131 fecal samples from 28 patients and 4
donors after first study treatment. *, p<0.05, ** p<0.01 for relative abundance differences 7 days
after therapy between SI and RI groups using Mann-Whitney U test. TMP-SMX, trimethoprimsulfamethoxazole.
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However, with one exception, all of these ASVs were absent in the donors by both culture and
metagenomics, allowing them to reliably measure the trajectory of the patient-associated ASVs.
The ASV corresponding to the cultured E. coli isolates was found in one donor, and it was
identified metagenomically in one donor (donor 1-1-DP) at 0.1% abundance. Accordingly, the
two patients (patient IDs A2 and A26) receiving that product were not considered for eradication
analysis for that ASV because we cannot distinguish between donor-derived E. coli and
recipient-derived E. coli. Given the recent FDA alert of resistant E.coli infections after receipt of
FMT [263], we confirmed that neither of these patients developed invasive infections from this
organism. Excluding the donor-origin ARO and matched recipients, each other recipient sample
that cultured an ARO was also positive by metagenomic sequencing, validating this mapping
technique. Culture, however, detected AROs from these species in only 26/111 (23.4%) of the
instances where that ASV was identified in the metagenomes. This may reflect differences in
isolate viability in the stored fecal samples since dead cells will yield positive DNA-based
detection. Alternatively, this may also reflect that ASVs for these species include both AROs and
antibiotic susceptible forms of these bacteria. Thus, with this approach, the identified ASVs
represent an upper-bound for detection of these potential AROs in the metagenomes.
After the first dose of RBX2660, the relative abundance of each isolate-based ASV diminished
sharply (Fig. 2.5F-J). For each of these ASVs found in an individual’s earliest sample (n=61
positive/130 total), if that ASV was undetectable in the patient’s last sample, it was considered
eradicated. By this metric, 41/61 or 67% of these species were eradicated (Table S4). During the
course of this study, 5 ASVs that were negative in both donors and in the patient’s earliest
timepoints later became positive (3 Enterobacter ASV 15, 2 Escherichia ASV 4). These were
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considered either undetectably low abundance by metagenomic sequencing or environmentally
acquired.
Despite the early decrease that we observed for ASVs corresponding to Enterococcus,
Escherichia, and Enterobacter, some patients showed later variable increases in their abundance
over time (Fig. 2.5F,G,J). Their respective eradication rates were 7/8 (87%), 9/22 (40%), and 7/10
(70%). However, Pluralibacter and Citrobacter both remained at extremely low abundances (<
1% and .02%, respectively) following the initial depletion (Fig. 4H-I), with eradication rates of
5/6 (83%) and 7/7 (100%), respectively. Interestingly, despite the trend towards ARO decrease
regardless of the outcome of first treatment, we found a significant difference in the relative
abundance of both Escherichia (Fig. 2.5G, p<0.01) and Pluralibacter (Fig. 2.5I, p<0.05) ASVs
between SI and RI groups at 7 days post treatment. This finding corroborates the above analyses
that sharp decreases in these genera may be associated with success whereas increased abundance
at 7 days correlates with likelihood of failure of RBX2660. After 2nd study drug in the RI group,
ASVs corresponding to Escherichia, Citrobacter, and Enterococcus did not decrease as
dramatically with variable levels thereafter especially for Escherichia (Fig. S8). ASV tracking in
metagenomic samples allowed us to quantitatively assess the maximum possible abundance of
these potential healthcare-associated infection causing organisms. Importantly, this method of
ASV tracking does not simultaneously measure phenotypic antibiotic resistance. As
aforementioned, if patients carried closely related susceptible strains that were not found in the
healthy donors, these could inflate the ASV totals. Nevertheless, this apparent rebound effect in
ARO abundance that we identified via deeply sequencing isolates is especially important to
consider when attempting to eradicate AROs completely from patient microbiomes via donor
microbiota transfer. Furthermore, this method of tracking ASVs of predicted AROs in
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metagenomic samples is sensitive and robust to false negatives, and so it identifies frequent
eradication and an overall decrease in AROs after microbiota-restoration therapy. We next
proceeded to assess whether overall ARG content and identity decreased concomitantly with
decreasing ARO abundance.
2.5.4 Antibiotic resistance gene abundance decreases over time commensurate with adoption
of donor microbiota
We annotated and quantified ARGs in each shotgun metagenome using ShortBRED with ARG
markers built from the CARD database [25]. The most abundant ARG families (as determined by
marker count per million reads) corresponding to major antibiotic classes were chosen for
representation in Figure 2.6A. For each gene family, the normalized gene abundance of all samples
at timepoint 0 was compared to all samples from successful treatments (SI group) at timepoint 180
and to all donor samples (Fig. 2.6A-B). We chose to examine 180 days after intervention because
prior research has shown microbiome recovery for healthy adults after antibiotic exposure [159].
For vancomycin, where multiple genes are required for functional resistance, the minimal
complete cluster had to be present to be counted in this analysis. In every gene family, the
abundance at timepoint 0 in patients was significantly different than in donors; and by timepoint
180, the abundance of that gene family in the patient had more closely approached that in the donor
(Fig. 2.6A-B; pairwise Wilcoxon with Benjamini Hochberg correction, p<0.05). This was not
always a decrease over time. Tetracycline resistance genes were most abundant within the donors
and were gradually adopted by the recipients (Fig. 2.6A). Tetracycline resistance is commonly
observed among healthy individuals given the inherent resistance of the most common microbial
taxa [165, 321]. Within the ß-lactamases, opposite effects were seen based on the origin of those
genes, where AmpC-type ß-lactamases were depleted while CblA genes were acquired and
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enriched (Fig. 2.6B). Altogether, the overall mean abundance of ARGs decreased families within
the b-lactamase class show opposite trajectories (N=21 patients and 4 donors). over time (Fig.
2.6C), but not significantly in those patients requiring a repeated intervention nor after 2nd study
drug (Fig. S9). However, the best predictor of ARG carriage was not time from intervention but
microbiota DFD. We observe a negative linear correlation between adoption of donor microbiota
conformation as measured by 1-DFD closest to 1 (indicating increased donor similarity) and ARG
carriage (Fig. 2.6D). The ARG burden therefore parallels the progress of RBX2660 engraftment
as measured by 16S rRNA gene-based distance from donor (Fig. 2.2), showing a significant
correlation in a linear mixed effects model (LR 17.68587, p<0.0001). This overarching correlation
holds true regardless of treatment status or origin of the ARGs. However, the strongest decrease
was seen in patient-origin ARGs. There was no relationship between donor distance and the ARGs
not present in baseline samples or donor (Fig. S10). The rapidly changing patient microbiota
samples had approximately 1 to 2 orders of magnitude greater variation than donor samples taken
over the same time frame (Table S5). We therefore observe a strong ability of the donor microbiota
to displace ARGs in the recipient, with the strength of this effect contingent on engraftment of the
donor microbiota. Therefore, we have documented the ability of donor microbiota to reduce ARO
species and ARG abundance as a collateral benefit of RBX2660 when successfully administered
for prevention of recurrent CDI.
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Figure 2.6. Antibiotic resistance gene abundance correlates with distance from donor. A)
ARGs were quantified in metagenomic sequences (N= 21 patients and 4 donors) and summarized
by mechanism. All ARG counts were transformed by log (ARG+1) for visibility. B) two gene
families within the b-lactamase class show opposite trajectories (N=21 patients and 4 donors). C)
Patient origin ARGs shown over time after RBX2660. D) ARG abundance is plotted versus 1(Distance from donor) using weighted UniFrac. A generalized mixed effects log normal regression
model of the formula ARGs ~ DFD + (1| PatientID) is shown, where DFD was significantly
predictive of and correlated with ARG count compared to the null model (Chisq=72.28,
d.f.(full)=1, p<2.2x10-16). For C and D, all patients of both outcome groups were included for 153
total samples with patient N=25 and donor N=4. A-C) Significance was determined by pairwise
Wilcoxon with Benjamini-Hochberg correction. *, p<0.05; **, p<0.001.
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2.6 Discussion
Microbiota transplantation has been utilized with great success to prevent recurrent CDI in many
different trials and population subsets [291, 322, 323], albeit placebo-controlled clinical trial data
[324] are still limited. However, suppression of blooms of C. difficile that cause CDI symptoms is
not the same as pathogen eradication, nor does it necessarily operate by the same mechanism as
would successful eradication or even suppression of ARO abundance. To characterize the effects
and influences of this procedure on ARGs and carrier microbes, we have tracked bacterial
taxonomic composition, microbial functional pathways, ARO colonization, and ARG abundance
within the human gut microbiome for 6 months after the procedure. To aid in discerning
directionality of association, we analyzed a cohort with variable engraftment, which can be
leveraged as a dose-response relationship between treatment and effects from the gut microbiota.
Engraftment of the donor microbiota was determined via 16S rRNA gene sequencing of the patient
and donor, and calculation of weighted UniFrac distance from donor (DFD) 7 days after product
delivery. Patients with successful RBX2660 treatment were distinguishable from those who
required further treatment based on their microbiome taxonomic and functional composition one
week after treatment (Figs. 2.2-2.4). Furthermore, we have identified key taxa associated with CDI
treatment outcomes. Specifically, members of the Lachnospiraciae family (Blautia spp.,
Roseburia, and Anaerostipes) were correlated with success whereas high abundance of
Proteobacteria (Escherichia, Klebsiella, and Pluralibacter) at day 7 was associated with necessity
of additional treatment in this cohort (Figs. 2.3 and 2.4).
The taxonomic restructuring was dominated by reduction of Enterobacteriaceae initially after
therapy (Fig. 2.5). These species are known to bloom after use of antibiotics, and their presence in
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high numbers at baseline is expected in this cohort. Our observation that increased pathways
dedicated to flagellin and motility are associated with treatment failure is consistent with the
knowledge that Proteobacteria such as E. coli and Klebsiella are often flagellated and motile (Fig.
S3). In treatment of this dysbiosis, the Enterobacteriales give way to Firmicutes, particularly
Lachnospiraciae. It has been previously demonstrated that Blautia obeum expresses bile salt
hydrolases that have been shown to suppress C. difficile germination in animal models [325].
Another important player is Akkermansia muciniphila, which has been inversely associated with
mucosal membrane pathology in multiple gastrointestinal disorders [326, 327]. Specifically,
Akkermansia spp. are important for mucin degradation, and their relative absence is associated
with insulin resistance, diabetes, and inflammatory bowel disease in both human cohorts and
animal models (reviewed in [328]). In this cohort, healthy donors and patients with successful
donor engraftments contain stable lower levels of Akkermansia muciniphila, while pre-treatment
samples and potentially dysbiotic microbiomes (high microbiota DFD) have widely varying levels.
We speculate that in this instance, Akkermansia is a surrogate for microbiome health, a hypothesis
that would require further validation in other cohorts and models. C. difficile itself was not among
the microbial taxa with strong associations to CDI symptoms. This could be because sampling
often occurred days or weeks apart from reported CDI symptoms (Fig. 2.1). Restoration of the
microbiome to a healthy configuration as quantified by low microbiota DFD is the best
microbiome correlate with symptom reduction that we identified. That sporulation was a positive
predictor of success is intriguing because it may suggest that colonization resistance to C. difficile
may be enhanced by other sporulating bacteria, as has been speculated in development of more
defined probiotic cocktails for treatment of CDI [23, 293, 329, 330]. In this sample set of 29
patients, those whose microbiota DFD reduced by less than 20% by day 7 were more likely to
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require further treatment (Fig. 2.2B). In support of this, increased abundance of Bacteroidia and
Clostridia seven days after RBX2660 correlated with a recurrence-free interval in a prior study
[310]. Thus, our study identifies several taxa correlated with FMT success or failure that can be
evaluated in larger, placebo-controlled studies.
The overall convergence of patient microbiomes with donors in both taxonomy and
microbial functional pathways was concordant with a competitive mechanism of donor microbial
engraftment similar to that identified by Smillie et. al [172]. Previous literature has demonstrated
that the efficacy of FMT on CDI symptoms depends on engraftment efficiency [172], and we
corroborate that here with this investigational microbiota therapeutic. Another intriguing finding
supported by this study is that over the follow-up period after treatment, patients can and do acquire
both taxa and ARGs that were not present at baseline or in the donor [172]. In this study, those
taxa and ARGs (Fig. S10) did not show any engraftment completion related trends, so they
behaved differently than either patient or donor origin. These taxa and genes could either be
undetectably low at baseline and in the donor, or they could come from the environment. This
highlights the potential importance of patient’s environment after FMT for determining and
maintaining a healthy gut microbiota composition.
We hypothesized that microbiota restoration would be accompanied by a decrease in ARO
and ARG carriage. This hypothesis was indeed true with greatest impact when the recipient’s
microbiota adopted a conformation similar to the donor at 7 days after therapy (Figs. 2.5-2.6). This
observation underscores the dramatic and immediate restructuring of the microbial ecology of the
gut following a successful FMT in all three levels of taxonomy, microbial metabolism, and ARG
carriage. In order to better address the impact of the FMT intervention and fates of ARO and ARG
thereafter, a placebo group should be included in future studies [324]. Post-FMT microbiota
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composition is dictated largely by abundance in the donor and recipient. ARG abundance was
higher before treatment, and after RBX2660 was directly correlated with DFD. That is, better
engraftment of the FMT lead to a more donor-like conformation and reduced ARG abundance. For
AROs, we did not observe this universally. We instead found that for VRE and ARO
Enterobacteriaceae, relative abundances as high as 40% were reduced by donor product. Thus,
outcome of FMT is not exclusively based on taxonomic abundance of either the donor or recipient
prior to administration.
The effects of microbiota restoration on AROs is a topic of hope and contention in the literature
[331]. We add to that body of literature ASV tracking of potential AR pathogens and longitudinal
relative abundance from well-sampled 16S rRNA gene sequencing, which is among the most
sensitive detection methods available. The eradication rate from all cultured ARO taxa (67%) was
within the wide range of 37.5-87.5% expected based on FMT for any condition [331]. Between
genera of AROs in this study, eradication rates varied from 40% in Escherichia to 100% in
Citrobacter. The slight rebound of relative abundance found in 3/5 of tracked ASVs at 180 days
would potentially be undetectable by culture. Yet this rebound could be clinically important, as
further antibiotic selection on a patient with incomplete eradication could be riskier than on a
patient who has been successfully decolonized. Importantly, while we only cultured ARO E. coli
from one donor product (compared to 40 other ARO isolates from patients), we did
metagenomically detect this ARO ASV in both of the recipients of this donor product. This finding
is especially important after two individuals suffered bacteremia from ESBL producing E. coli
present in donor FMT resulting in the FDA requiring donor screening questionnaires and MDRO
testing of donor stool [262, 263]. This finding highlights the importance of screening donor
products for ARO isolates to reduce their risk of acquisition by recipients. Establishing appropriate
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detection thresholds for bacteria targeted for donation, eradication, and replacement is therefore
critically important in these studies.
This study presents taxa and microbial functional pathways that require larger datasets and further
validation prior to incorporation into clinical practice. Furthermore, sample storage conditions and
freeze-thaw cycles have been shown to decrease certain taxa, especially Bacteroidetes [332],
which is an inherent limitation of performing microbiome analyses on archived fecal samples.
Additionally, this study did not include a placebo group that did not receive FMT in order to
characterize the natural history of ARG and ARO decrease after finishing a course of antibiotics.
The abundance of ARGs in the gut microbiome was even more clearly responsive to treatment in
a strong inverse relationship to engraftment, as measured by DFD. It is reasonable that both
shedding and transmission of microbes reduces when they are present at lower abundance in the
gut, but the epidemiology of this remains unquantified. The high initial burden of ARGs and AROs
in CDI patients [255], along with growing incidence (and/or reporting) of CDI [333], is an
important additional motivation for global surveillance of AR and development of methods to
combat its spread. Finally, most microbiome analyses to date have focused on metagenomic
sequencing of bacteria in stool samples, but emerging research suggests that viruses, prokaryotes,
and small molecules can also meaningfully impact health and disease [7, 54]. Therefore, future
studies should consider a multi-omics and multi-kingdom approach to better predict outcomes after
FMT to both restore microbiome health and limit ARG and ARO carriage.

2.7 Conclusions
We have demonstrated here that in addition to the important prevention of recurrent CDI, when
the donor microbiome optimally engrafts after microbiota-restoration therapy, ARG and ARO
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abundance in the recipient gut microbiomes substantially decrease. Abundance of ASVs
corresponding to species that are potentially multi-drug resistant in baseline samples were
immediately reduced and often to undetectable levels, but a late rebound for some patients
indicates incomplete eradication. Further studies are needed to quantify epidemiological benefits
such as decreased transmission to other people and the environment. Thus, RBX2660 and
microbial therapeutics in general represent an effective method to alter the gut community
composition together with all its metabolic and potentially pathologic attributes. The abundance
of ARGs and AROs can potentially be lastingly reduced with this method, making it a promising
tool in combating the global threat of antibiotic resistance.

2.8 Availability of data and materials
The 16s rRNA and raw genomic, metagenomic DNA dataset generated/and or analyzed during the
current study are available in the NCBI repository under BioProject PRJNA674880 [296]. The
genome isolate assemblies are available in the NCBI repository under BioProject PRJNA693986
[304].
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Additional file list and legends

Fig. S1. Study protocol for Phase II clinical trial NCT01925417 adapted from reference [228].
Samples specifically used for this study depicted in Fig. 2.1.
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Fig. S2. The relative abundance of bacterial phyla in all patients are shown at day 0 (panel A)
and in all donor samples from the 4 donors (panel B). The patient IDs are marked in gray if
symptoms resolved in a single dose of the study drug and in red if they required repeat
intervention. A) Patient ID is listed after the letter A on the x axis with relative abundance of
each phylum in stacked bar chart format on the y-axis. B) Donor samples are named as donor
number.samplenumber followed by DS for donor substance.
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Fig. S3. linear discriminant analysis compares functional pathway abundance, as annotated by
HUMAnN2 and visualized with LEfSe, at day 7 between the two outcome groups. In red are
pathways more enriched in the reintervention (RI) group, while those patients who recovered
after a single treatment had a significantly higher abundance of the pathways in green.
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Fig. S4
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Fig. S4. Shown are the HUMAnN2 functional pathway abundances for all patients with both day
0 and day 7 samples.

84

A

Fig. S5

B

Fig. S5. The relative abundance of Akkermansia muciniphila ASV 2 is shown over time stratified
by outcome. A) The patient IDs are marked in gray if symptoms resolved in a single dose of the
study drug, in red if they required repeat intervention, and black if they come from the donor. B)
Akkermansia muciniphila ASV2 abundance after re-intervention.
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A

B
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f_Enterobacteriaceae ASV_15
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Fig. S6. The PCA analysis from Main Figure 2 is reproduced here via the dual principal
component function of phyloseq, which uses Euclidean distances. The overall taxonomic
composition is graphed in Panel A, while Panel B shows the directionality of the influence of
individual taxa upon those samples.
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A

B

Fig. S7. A) The relative abundance of Clostridioides difficile is tracked here using species-specific
toxin genes detected in metagenomic sequences via ShortBRED. The gene count was normalized
to the number of metagenomic reads and expressed in terms of copies per metagenome. B) The
relative abundance for the ASV corresponding to C. difficile is shown in the bottom panel. The
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patient IDs are marked in gray if symptoms resolved in a single dose of the study drug and in red
if they required repeat intervention.
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Table S1 This table shows cultured isolates, their associated ASVs, their taxonomy assignments according to DADA2 and MALDI-

Final taxonomy assignments were confirmed by genomic alignments with type strains.

TOF, and antibiotic sensitivity results in terms of their clearance zone sizes and the interpretations of sensitive, intermediate, or resistant.

89

Position
850..1641

Phenotype
Aminoglycoside resistance

Accession
JX185132

A1-2-60

blaCTX-M-15

100

876/876

2174..3049

Beta-lactam resistance
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msr(C)
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Macrolide, Lincosamide and AY004350
Streptogramin B resistance

A3-1-7
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A3-1-7

tet(U)

99.06
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VanS-A
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VanY-A
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VanX-A
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VanH-A

100
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VanR-A
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VanA
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7_cov_533.274
1155/1155 NODE_138_length_232
6_cov_285.647
912/912
NODE_134_length_245
7_cov_319.124
609/534
NODE_168_length_141
0_cov_239.998
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NODE_191_length_103
6_cov_282.579
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NODE_138_length_232
6_cov_285.647
1032/871 NODE_168_length_141
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486/486
NODE_134_length_245
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NODE_184_length_110
8_cov_231.916
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NODE_191_length_103 1..628
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99.9

1244..2275

M97297

A6-1-0

VanR-A

100

A6-1-0

VanX-A

99.82

A6-1-0

VanH-A

100

Vancomycin resistance
(Glycopeptid resistance)
Vancomycin resistance
(Glycopeptid resistance)
Vancomycin resistance
(Glycopeptid resistance)
Vancomycin resistance
(Glycopeptid resistance)

A6-1-0

VanZ-A

100

486/486

NODE_104_length_500 3209..3694
5_cov_153.188

Vancomycin resistance
(Glycopeptid resistance)

FJ866609

A6-1-0

VanY-A

100

912/912

NODE_104_length_500 3847..4758
5_cov_153.188

Vancomycin resistance
(Glycopeptid resistance)

M97297

A6-1-0

VanS-A

100

1155/1155 NODE_153_length_180 561..1715
9_cov_104.775

Vancomycin resistance
(Glycopeptid resistance)

M97297

NODE_167_length_145 827..1450
0_cov_348.095

AF299292

80935..82854 Tetracycline resistance

FN433596

813..1130

Tetracycline resistance

U01917

1078..2232

Vancomycin resistance
(Glycopeptid resistance)
Vancomycin resistance
(Glycopeptid resistance)
Vancomycin resistance
(Glycopeptid resistance)
Vancomycin resistance
(Glycopeptid resistance)
Vancomycin resistance
(Glycopeptid resistance)
Vancomycin resistance
(Glycopeptid resistance)
Vancomycin resistance
(Glycopeptid resistance)
Aminoglycoside resistance

M97297

NODE_229_length_588 1..565
_cov_305.462

Aminoglycoside resistance

AF330699

NODE_156_length_171 357..1094
7_cov_287.743

Macrolide resistance

AF299292

NODE_175_length_124
0_cov_171.042
1155/908 NODE_193_length_100
2_cov_205.478
486/486
NODE_116_length_358
5_cov_269.609
969/754
NODE_190_length_103
6_cov_226.709
1479/1479 NODE_48_length_2051
0_cov_27.6943
1920/1920 NODE_4_length_83112
_cov_25.6588
318/318
NODE_144_length_205
7_cov_483.839
1032/1032 NODE_127_length_282
1_cov_99.258
696/583
NODE_153_length_180
9_cov_104.775
609/541
NODE_127_length_282
1_cov_99.258
969/969
NODE_127_length_282
1_cov_99.258

1299..2210
1..534
283..1036
405..1100
540..1410
661..1146
140..934

1..871
1..908
2678..3163
283..1036
6104..7582

1..583
2281..2821
283..1251

M97297
FJ866609
FJ866609
FJ866609
FJ866609
FJ866609
M26832

Macrolide, Lincosamide and AY004350
Streptogramin B resistance
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M97297
FJ866609
FJ866609
AY004350
FN433596

FJ866609
FJ866609
FJ866609

Only the top 41 rows are shown out of 350. Full file available upon rquest.

Contig
NODE_156_length_408
7_cov_26.3466
NODE_52_length_3012
8_cov_20.2628
NODE_229_length_909
_cov_37

genomic location, predicted phenotype, and % identity to reference genes.

Identity Query
100
792/792

Table S3. All genomic resistance gene annotations from Resfinder for all MDRO isolates are listed here, with their specific

Sample_hyphen Gene
A1-2-60
aadA1

PatientID
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
A13
A14
A17
A18
A19
A20
A21
A23
A24
A26
A27
A28
A29
A30
A31
A32
A33

First_Sample
A1.2.60
A2.1.7
A3.1.7
A4.1.0
A5.1.7
A6.1.0
A7.1.7
A8.1.0
A9.1.0
A10.1.0
A11.1.0
A12.1.0
A13.1.7
A14.1.0
A17.1.0
A18.1.0
A19.1.0
A20.1.7
A21.1.7
A23.1.0
A24.1.0
A26.1.7
A27.1.0
A28.1.0
A29.1.4
A30.NA.NA
A31.1.0
A32.1.0
A33.1.0

Last_Sample
A1.2.60
A2.2.60
A3.2.180
A4.2.60
A5.2.180
A6.1.180
A7.2.180
A8.2.60
A9.1.180
A10.2.30
A11.1.180
A12.1.180
A13.1.180
A14.2.30
A17.2.180
A18.2.180
A19.1.180
A20.2.90
A21.1.180
A23.1.60
A24.2.180
A26.1.60
A27.1.30
A28.1.60
A29.1.180
A30.NA.NA
A31.1.180
A32.1.180
A33.1.14

f_Enterobacteriaceae ASV_15
Insufficient data points
Absent
Absent
Absent
Absent
Absent
Absent
Eradicated
Acquired
Acquired
Eradicated
Not Eradicated
Absent
Absent
Absent
Eradicated
Absent
Absent
Not Eradicated
Absent
Eradicated
Acquired
Not Eradicated
Eradicated
Eradicated
Insufficient data points
Absent
Absent
Eradicated

g_Citrobacter ASV_140
Insufficient data points
Absent
Absent
Eradicated
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Eradicated
Eradicated
Absent
Absent
Eradicated
Absent
Eradicated
Absent
Eradicated
Absent
Absent
Eradicated
Insufficient data points
Absent
Absent
Absent

g_Enterococcus ASV_20
Insufficient data points
Eradicated
Eradicated
Absent
Eradicated
Eradicated
Eradicated
Absent
Not Eradicated
Absent
Absent
Absent
Absent
Absent
Eradicated
Absent
Absent
Absent
Absent
Absent
Eradicated
Absent
Absent
Absent
Absent
Insufficient data points
Absent
Absent
Absent

g_Escherichia/Shigella ASV_4
Insufficient data points
Masked
Not Eradicated
Acquired
Not Eradicated
Not Eradicated
Not Eradicated
Absent
Not Eradicated
Not Eradicated
Not Eradicated
Not Eradicated
Eradicated
Not Eradicated
Eradicated
Eradicated
Eradicated
Acquired
Eradicated
Eradicated
Not Eradicated
Masked
Not Eradicated
Eradicated
Eradicated
Insufficient data points
Eradicated
Not Eradicated
Not Eradicated

g_Pluralibacter ASV_43
Insufficient data points
Absent
Eradicated
Absent
Eradicated
Eradicated
Eradicated
Absent
Not Eradicated
Absent
Eradicated
Absent
Absent
Eradicated
Eradicated
Absent
Absent
Eradicated
Absent
Absent
Eradicated
Absent
Not Eradicated
Eradicated
Absent
Insufficient data points
Absent
Absent
Absent

Table S4. The eradication status of ARO found in each patient is summarized here. If the first
sample (notated as Patient ID – Dose number – Days from previous dose) was positive according
to the ASV quantified by DADA2 and the last sample from the same patient was negative, the
status for that ASV is shown as negative. Acquired means it was first negative (in both patient and
donor) and later positive, absent means all samples were negative, masked means the donor was
positive, and insufficient samples means the first and last sample were the same.
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A

Fig. S8
B

C

D

Fig. S8. Relative abundance of ASVs corresponding to A) Enterobacteriaceae, B) Escherichia, C)
Citrobacter, and D) Enterococcus tracked temporally after second dose of RBX2660 in the RI
group.
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Fig. S9
A RI Group; FMT 1
Patient origin ARGs over time
ns

ns

ns

7

30

60

9

Log(ARGs + 1)

8

7

6

5

4

0

Days after therapy

B RI Group; FMT 2
Patient origin ARGs over time
ns

ns

ns

ns

ns

30

60

90

180

Log(ARGs + 1)

7.5

5.0

2.5

0.0
0

7

Days after therapy

Fig. S9. Patient origin ARGs over time after A) first RBX2660 and B) second RBX2660 in the
RI group. All comparisons non-significant as determined by pairwise Wilcoxon with Benjamini
Hochberg correction. n = 17 total patients with A) 27 and B) 45 samples.
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Fig. S10. Abundance of resistance genes in each metagenomic sample compared to their DFD for
resistance genes that were not detected in patients’ day 0 samples or in the donors. For these genes,
their abundance and the distance from donor are uncorrelated.
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Patient
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
A13
A14
A17
A18
A20
A21
A23
A24
A26
A27
A28
A29
A33

904.98
4251.2
931.14
434.76
0

NA
NA
NA
3038.3
NA
13085
NA
2919.9
10563
11998
6703.9
6472.2
NA
5960.7
8472.3
10941
NA
NA
10366
2083.1
NA
4096.6
3827.8
NA
3033.8

0
NA
NA
NA
NA
NA
NA
7793.2
1355.5
NA
1338.5
NA
NA
NA
NA
NA
NA
NA
NA
NA
3342.8
NA
NA
NA
NA
NA

Unprocessed donor samples in temporal order
Std Deviation Variance
900.54 851.14 732.63 944.05 919.2228442 NA
NA
76.3069077 5822.74
876
885 908.41
1432 NA
NA
NA
1461.681494 2136513
424.97 2395.6 612.56 1720.4
314.141212 837.86
376.3 738.6373635 545585
351.13 NA
NA
NA
NA
NA
NA
59.14136328
3497.7

Days after 1st therapeutic dose
7
14
30
60
NA
NA
NA
NA
NA
NA
2147.1 NA
NA
NA
NA
10191 NA
NA
NA
NA
1693.9 NA
NA
NA
NA
5144.2 NA
NA
NA
NA
NA
NA
678.51 967.8518317
NA
18975 NA
NA
NA
NA
1685.2 NA
NA
NA
NA
461.04 NA
534.55
481.801461
NA
9728.6 NA
NA
1876.887994
NA
7017.4 NA
3697 809.1793103
NA
970.96 NA
12838 610.2171726
NA
571.56 NA
362.99 460.9615771
NA
3079.8 NA
1708.8 4307.998888
NA
1566.9 NA
NA
NA
NA
NA
NA
NA
NA
NA
1725.8 NA
NA
NA
NA
2719.3 NA
2228.7 697.1441734
NA
1003.2 NA
1304.3 823.4503346
NA
2058.9 NA
NA
NA
NA
205.29 NA
NA
12490.05168
NA
1854.4 NA
5572.7 NA
NA
1620.6 NA
NA
1164.510075
1471.7 3942.6 NA
NA
704.815889
NA
NA
1410.4 NA
NA
4

Days after 2nd therapeutic dose
7
30
60
90
NA
NA
7486.6 NA
30299 NA
2286.6 NA
2986.7 NA
1573.9 NA
30007 619.18 860.81 NA
1344.2 2442.1 NA
NA
NA
NA
NA
NA
1884.1 8024.8 18920 3633.5
NA
4572.2 1134.4 NA
NA
NA
NA
NA
11899 1073.6 NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
897.72 NA
NA
NA
1178.9 1952.3
4405
3183.3 2119.7 2176.7 NA
1445.6 1304.1 1719.6 12625
NA
NA
NA
NA
NA
NA
NA
NA
2316.9 2571.3 1596.7 NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

90
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1420.3
NA
NA
NA
NA
NA
NA
1566.9
NA
NA
NA
NA
NA
NA
NA

180
NA
NA
NA
NA
NA
784.75
NA
NA
107380
NA
1434.6
1740.9
578.65
NA
NA
NA
NA
3451.9
NA
NA
NA
NA
NA
1093.8
NA

180 Std Deviation Variance
NA
NA
NA
NA
16213.64584 3E+08
16872 7069.006673 5E+07
NA
12760.0345 2E+08
1221.8 1821.977555 3E+06
NA
6138.609082 4E+07
3324.6 7210.447496 5E+07
NA
1429.184049 2E+06
NA
46879.0039 2E+09
NA
5423.25401 3E+07
NA
2775.106271 8E+06
NA
5210.68877 3E+07
NA
102.3638629 10478
NA
2024.060196 4E+06
1476.2 2846.952501 8E+06
817.28 4053.520414 2E+07
NA
4956.831434 2E+07
NA
1057.655956 1E+06
NA
4665.379538 2E+07
1679.7 593.9715813 352802
NA
8686.636449 8E+07
NA
1872.271292 4E+06
NA
1424.348191 2E+06
NA
1460.19092 2E+06
NA
1147.926655 1E+06
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Table S5. These tables show the total ARG hits in RPKM for donors and patients at each sample
collection timepoint, as well as the standard deviation and variance over time.

Donor
D1
D3
D4
D5

Chapter 3
The impacts of prophylactic amoxicillin on the gut
microbiota in childhood severe acute malnutrition

This chapter contains the following ongoing project:

Langdon A*, Schwartz DJ*, Sun X, Isanaka S, Dantas G. The impacts of prophylactic
amoxicillin on the gut microbiota in childhood severe acute malnutrition. Manuscript in
preparation for Microbiome (est. May 2021).

*The first two authors will contribute equally to this work.
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Collaboration statement
The randomized clinical trial was conceived and conducted by and Sheila Isanaka with Medecins
Sans Frontiers in collaboration with the Niger Ministry of Public Health. AL designed the follow
up sample and metadata collection, which again was performed by SI with MSF. AL and XS
extracted DNA and made sequencing library preparations for all of the samples. AL performed all
analysis and early writing drafts under mentorship of GD. DJS has contributed to writing, editing,
figure interpretation, clinical consultation, and literature review.

3.1 Introduction
Severe calorie restriction during the first years of life has devastating long-term consequences
including decreased educational attainment, growth stunting, and diminished economic
productivity in the survivors [334]. In 2019, UNICEF estimated that 47 million children suffered
from wasting and 14.3 million were severely wasted. Severe acute malnutrition (SAM) increases
risk of mortality by up to 50% for other leading causes of death, and it is attributed 3.1 million
deaths per year [335]. Immune dysfunction due to malnutrition can make minor infections
dangerous, and extreme poverty can make expensive medications inaccessible. Even when
children with SAM are enrolled in nutritional therapy programs, relapse and mortality remain
extremely high after discharge [336]. Temporary provision of food alone is not enough. In addition
to addressing socioeconomic factors, and undernourished child has an undernourished gut
microbiome that may not recover on its own.
In healthy children, the gut microbiome develops along with the child, following a defined
trajectory and increasing in diversity [37]. Within geographically-restricted regions, the correlation
between the microbiome and the age of the child is strong enough that one can predict the other
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[38]. With this in place, it quickly became obvious that the gut microbiome of malnourished
children was markedly different in a systematic manner—the malnourished microbiome shows an
'age regression'—where it resembles the composition of a younger child [38].
In 2012 a randomized control trial for antibiotic intervention in malnutrition began in Malawi, and
this showed a significant reduction in mortality in children with uncomplicated SAM who had
received amoxicillin or cefdinir [337].The mechanism for this benefit is unclear. One hypothesis
suggests that in malnourished children who are being transitioned from breastfeeding to solid food,
an age regressed microbiome may not be able to aid in digestion of a child’s current diet. Another
proposes widespread subclinical infections with enteric pathogens, as a malnourished child’s
weakened immune systems may not show typical symptoms of an infection. However, these
effects appear to vary in strength between studies. The beneficial effect of amoxicillin in
uncomplicated marasmus in Niger was small enough to leave doubt about the cost/benefit ratio to
these children [338]. Differences in population characteristics such as preponderance of proteinonly deficiency (kwashiorkor) and underlying chronic disease like HIV could reverse this benefit.
Furthermore, none of these studies had the ability to quantify the potential repercussions of this
prophylactic antibiotic use in terms of antibiotic resistance.
These uncertainties motivated the microbiome analysis on a subset of that same Niger trial that is
presented here, with the goals of 1) quantifying the risk of antibiotic resistance and 2)
understanding why and how amoxicillin affects the outcomes of SAM. Due to both intrinsic and
acquired resistance, amoxicillin is fairly limited in both scope and scale of its effects on the gut
microbiota. Therefore, it is not surprising that the effect size of the treatment would be slim and
potentially less noisy. All that was needed is for amoxicillin to have any significant demonstrable
effect on health outcomes. Isanaka et al. (2016) did in fact find significant effects from amoxicillin
98

upon the individual anthropometry on “short-term” WAZ and MUAC. For this ancillary
microbiome analysis, that is enough to proceed.
To determine the impact of amoxicillin prophylaxis on the gut microbiome and resistome, 164
children were recruited for a 12-week ancillary study with stool sampling (Figure 1), which was
later expanded to include healthy control and a two-year follow up timepoint. Our objectives in
this project are to 1) identify and quantify resistance genes within vulnerable populations; 2) model
the dynamics of ARG enrichment and persistence in response to antimicrobial treatment; 3) use
the taxonomy and metabolic data to test potential mechanisms; and 4) reassess the cost-benefit
ratio of prophylactic antibiotic use in these settings.

3.2 Methods
3.2.1 Study cohort description
The study cohort was a subset of a larger, previously published randomized clinical trial conducted
by Medecins sans Frontiers (MSF) [338] to evaluate the efficacy of amoxicillin vs. placebo in
aiding nutritional recovery from uncomplicated severe acute malnutrition. The study population
for both the larger trial and the microbiome ancillary cohort consisted of children between 6 and
60 months of age presenting to four MSF clinics in Maradounfa, Niger, with SAM. The original
trial recruited 2399 children, and for the microbiome analysis, 164 of these children were given
additional surveys and had fecal samples collected throughout the 12 week follow up period (Figs.
3.1 and 3.2). SAM was diagnosed based on the height and weight of the child compared to the
World Health Organization (WHO) Child Growth Standards (WHO 2012). These metrics are
typically expressed in standard deviations (Z scores) relative to either the child's age or height
99

[339]. The criteria for SAM for this study was stated as at least one of: a weight-for-height Z-score
of -3 or less or a mid-upper arm circumference of 115mm or less. To be defined as uncomplicated,
the child could not have any conditions requiring hospitalization, including bipedal edema. Other
inclusion criteria included the ability to complete the study (sufficient appetite, no sensitivity to
amoxicillin, living within 15km of the center, availability for 12 week follow up) and exclusion
criteria included a history of admission to a different nutritional program within 3 months,
antibiotic receipt within 7 days, currently on antibiotics for any reason, and congenital
abnormalities. For the microbiome analysis as in the main study, nutritional recovery was defined
as sustained improvement in either WHZ or MUAC past the previously defined threshold of severe
acute malnutrition on two consecutive visits. Mortality was used as a secondary endpoint, although
fortunately this event was too rare to compare between groups.

3.2.2 Trial design
Upon enrollment, an introductory survey was administered to gather essential metadata, and a stool
sample was collected and immediately frozen at -20ºC. The patients were given outpatient standard
of care [340], which in this study included high dose Vitamin A (100,000 IU for children < 4 kg
and 400,000 IU for children 4-8 kg, and 200,000 IU for children ≥ 8 kg), anti-helminthic treatment
(200 mg albendazole for children < 4 kg and 400 mg for children ≥ 8 kg), and 5mg folate
supplement once per week. They were given measles vaccination and treatment for malaria and/or
anemia if required. All enrolled children were given 2-3 sachets per day of Ready to Use
Therapeutic Food (RUTF, specifically Plumpy’nut® manufactured by Nutriset in Malaunay,
France) and a seven-day regimen of either 80mg/kg/day of amoxicillin or a placebo. The antibiotic
assignment was random and double-blinded. Follow-up visits occurred at 1, 2, 3, 4, 8, and 12
weeks, and an additional stool sample was collected at 1, 4, 8, and 12 weeks (Figure 3.2). Further
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information was collected on symptoms of illness, diet, and growth at each of these visits. Children
who recovered to WHZ > -2 or MUAC > 125 mm were graduated from Plumpy’nut®
supplementation and but still followed. Conversely, children whose WHZ score worsened for two
consecutive visits were transferred to inpatient care and considered lost to follow up.
Of the original 164 children in the microbiome study, 38 children from representative age ranges
and treatment groups were revisited for long-term follow up and fecal sampling at 2 years post
enrollment (Table 3.1). At that time, a child of the same household or village was identified
matching the original subject’s age at enrollment, and a fecal sample was collected from them to
establish a healthy microbiome age curve for the local pediatric population. To serve as temporal
control for a potential population wide microbiome drift, 12 children matching SAM entrance
criteria were surveyed and sampled at the same at MSF malnutrition centers.

3.2.3 Sample collection and handling
Stool samples were collected during home visits at the scheduled timepoints after start of
treatment. The Initial collection was in plastic 50mL Eppendorf tubes, which were placed in a
cooler (4 °C) for transportation back to the MSF treatment center. At the center, the stool samples
were aliquoted into prelabeled cryovials and frozen at -80 °C. After conclusion of the trial, all
collected samples were shipped on dry ice to Washington University in St. Louis. Samples were
thawed once directly into DNA extraction pipeline.
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Figure 3.1. Schematic of trial design for the original randomized controlled trial and enrollment
into the ancillary microbiome analysis (bottom tier).
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Figure 3.2. Stool sampling timeline for the 164 children enrolled in the ancillary microbiome
study. The double slash represents a large elapse of time before the two year follow up sample
collection.
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Table 3.1. This summary of the four types of patients shows the selection criteria for each cohort
and the timing of stool collection. Note that the 38 children with SAM are a subset of the main 164
SAM children.
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3.2.4 DNA extraction and sequencing
Stool samples were thawed at 4 °C just until aliquoting with a spatula was possible. Approximately
0.25g or half of stool if less than 0.5g was available sample was weighed into 2mL beadbeating
tubes with 250uL of 0.1mm zirconium beads (BioSpec Products, cat# 1107910z), 500uL of Buffer
A (200mM NaCl, 200mM Tris, 20mM EDTA), and 210uL of 20% SDS. Then 500uL of
phenol:chloroform:IAA (25:24:1, pH 7.9) was added to each sample, and all were placed on ice
for 5 minutes. Chilled samples were subjected to beadbeating at “homogenize” setting for 2
minutes, iced for 2 minutes, and then beadbeating for 2 more minutes. The samples were then
centrifuged at 4 °C at 6800rcf for 3 minutes. Phase-lock gel columns (5Prime, cat#2302820) were
prepared by centrifuging for 30 seconds at 20,800rcf to collect all gel at the bottom. The aqueous
phase of each sample, totaling about 600uL depending on stool water content, was then carefully
pipetted into the corresponding labeled PLG column. An equal amount of phenol:chloroform:IAA
(~600uL) was added, and the columns were mixed by inversion. The samples were then
centrifuged at 20,800rcf or max speed for 5 minutes, and the aqueous phase was pipetted into a
1.5mL Eppendorf tube. An equal amount (600uL) of isopropanol at -20 °C was added to each
sample along with 60uL of NaOAc. The samples were then frozen at -20 °C overnight (minimum
6 hours). The samples were centrifuged at maximum speed or 20,800rcf for 20 minutes, which in
most cases formed a large visible pellet. Regardless of whether the pellet was visible, the
supernatant was carefully pipetted off from the opposite site of the Eppendorf tube, and 500uL of
4 °C 100% ethanol was added. The samples were centrifuged for 3 min at 4 °C to ensure that any
pellet remained on the bottom, and then the supernatant again was carefully discarded. The samples
were allowed to air dry uncapped in a dark drawer for between 15 and 30 minutes. Finally, the
pellet was resuspended in a minimum of 30uL TE (up to 100uL TE for very large pellets) and
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incubated at 50 °C for 5 minutes. Samples were resuspended via pipetting up and down. Then each
sample was purified via the QIAQuick PCR purification kit with the following modification: prior
to use of Buffer PB, RNase was added to Buffer PB at 100mg/mL, and when the samples were
suspended in the modified PB, they were incubated for 2 minutes at room temperature before
adding to the purification column. Otherwise the standard protocol was followed. DNA was eluted
in EB buffer and quantified via the Qubit dsDNA broad spectrum system. The quantified DNA
was then ready to be processed for sequencing via the Illumina Hi-Seq platform.

3.2.5 Taxonomy and microbial functional pathway prediction
Shotgun metagenomic sequences were demultiplexed, trimmed and filtered using Trimmomatic
v0.33 [308] with the following parameters: leading and trailing sequences of 10bp, with a sliding
window between 4 and 20bp, and minimum length of 60bp. Deconseq v0.4.3 on hsref38 was used
to screen out any human DNA [45]. Kraken2 [22], a k-mer based exact sequence matching
algorithm, was then used to predict taxonomy down to the level of species. Functional pathways
of the gut microbiome were inferred using HUMAnN2 by mapping unassembled sequencing reads
to functionally annotated pangenomes [26].

3.2.6 Resistance gene prediction and quantification
ShortBRED protein markers were built from the Comprehensive Antibiotic Resistance Database
(CARD) 3.0 (02/2019 update) database using shortbred-identify.py with cluster identity 90% and
screened against Uniref90 (02/2019 update) [25]. ShortBRED-quantify normalizes reads based on
marker length and read depth in order to quantify abundance in metagenomic data. ARGs were
categorized according to mechanism and then by gene family as available in the CARD 3.0
ontology.
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3.2.7 Mixed effects modeling
The wealth of data types and variables in this project warrant mixed effects linear regression
modeling. The figures and statistics presented here were made through the nlme package in R
[341] and from the BioBakery’s MaAsLin2 for multivariable associations and linear regression,
which is specifically tailored for microbial community annotation and interpretation [342].

3.3 Results
3.3.1 Treatment with amoxicillin leads to immediate and sustained
improvement in anthropometry compared with placebo
Figure 3.3 shows an increase in MUAC immediately after amoxicillin that persists throughout the
observation period (Fig. 3.3). The preferred metric throughout this analysis is mid-upper arm
circumference, which for children under 5 does not depend on age and can therefore be used with
transformation into Z-scores [338]. As early as the first week of the study, gains in MUAC for the
amoxicillin treatment group outpace those of the placebo group from a qualitative standpoint.
Children who have received amoxicillin continue to outpace their counterparts throughout the
study (Figure 3.3). To test if the effect is significant, we employed generalized linear mixed effects
models using treatment group as a predictor of MUAC, controlled for longitudinal data with
subject ID as a fixed effect. Using this formula, treatment with amoxillin had a significant impact
on MUAC (effect size 1.87, p<.05). Further, MUAC predicts graduation as early as week 4
(p<.001). This means that for the microbiome analysis, MUAC can reasonably be used as an
indicator of recovery from SAM.
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3.3.2 Taxonomy and diversity
The next most pressing matter is to establish the ways in which the microbiomes of these children
with SAM are disrupted. Populations from different regions of the world can differ widely in gut
microbiome composition, so local healthy samples from at a variety of ages were needed. Age
brackets were created to mirror the distribution of ages from the children with SAM, and healthy
control subjects were chosen to match study participants according to the schematic in Table 1.
The healthy age matched cohort was used to create an age curve and a principal component
analysis, which shows the contribution of the most important bacterial taxa to age maturation
(Figure 3.4). As expected, the healthy microbiomes increased in diversity from 6 to 60 months,
with the youngest microbiomes dominated by Bifidobacteria.
Compared with the healthy subjects, the children with SAM began with a much higher proportion
of Proteobacteria (Figure 3.5), but they generally also showed acquisition of new taxa over time.
The administration of amoxicillin is frequently followed by a bloom in Proteobacteria, as
demonstrated by regression modeling (Figure 3.6). Diversity as measured by the Shannon index
also shows treatment group specific effects (Figure 3.7). At week 1, the impact of the amoxicillin
is seen in a nonsignificant drop in mean diversity, which is not seen in the placebo group. That
effect quickly resolves by week 4. At the two year follow up timepoint, subjects who received
amoxicillin have significantly improved diversity from baseline SAM (Mann-Whitney-Wilcoxon
test; effect size 1.57, p=.0007). The placebo group at year 2 is not significantly different from SAM
(effect size 0.147, p=.5867).
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Figure 3.3. Mid upper arm circumference (MUAC) improves in both treatment groups throughout
the study. In this figure, the vertical axis shows the average improvement in MUAC compared to
that child’s baseline at week 0. This qualitative difference remains visible throughout the 12-week
follow up period of the main trial. Longitudinal modeling was used to statistically test the
association of treatment group with MUAC (p<.05).
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Figure 3.4. This principle component analysis was created from the age curve of the healthy
control children age 6-60 months in Maradi, Niger. The vast majority of the variation in the gut
microbiota composition between ages can be attributed to Bifidobacteria, followed by Firmicutes.
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Figure 3.5. Example phylum-level taxonomic progression of subjects with SAM from week 0 to
12 of the study who received A) placebo or B) amoxicillin.
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Treatment group (0=placebo, 1=amoxicillin)

Figure 3.6. A mixed model linear regression associated the relative abundance of bacterial taxa
with the treatment group in a paired sampling of weeks 0 and 1 (fixed effect = treatment group,
random effect = subject ID). As expected, the largest qualitative effects of broad-spectrum
antibiotics were on Proteobacteria like Escherichia and Shigella, which not only have a high
carriage of resistance genes but are early opportunists after perturbation. Taxa were annotated with
Kraken2 and modeled via Maaslin2.
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Figure 3.7. The Shannon index of diversity shows a temporary, nonsignificant decrease at time
point one week in the amoxicillin group but the not the placebo. This does not persist. The mean
Shannon index for both treatment groups trends up over 12 weeks. At 104 weeks, with a smaller
cohort size of N=38, the Shannon index for diversity for the amoxicillin group is different than for
the SAM subjects collected at the same time (Mann-Whitney-Wilcoxon test; effect size 1.57,
p=.0007), but the same is not true of the placebo group (effect size 0.147, p=.5867).
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3.3.3 Antibiotic resistance
Baseline antibiotic resistance in Nigeran children
At week 0, before the start of any treatment, b-lactamases genes conferring resistance to
amoxicillin were present in at least one bacterial species in every single child. This finding is not
surprising, as even previously uncontacted indigenous tribes have been found to carry blactamases [138]. Slightly more alarming is the presence of extended-spectrum b-lactamases
(ESBLs), which inactivate penicillins, first, third-, and fourth-generation cephalosporins, and
aztreonam. ESBL-expressing Enterobacteriaceae are rising in global prevalence, are common in
Asia and sub-Saharan Africa, and are listed by the CDC as serious threats [167, 343, 344]. The
remaining b-lactamases antibiotics (cephamycins and carbapenems) are expensive enough to be
prohibitive for this population. ESBLs were again found in every single child at baseline. The
specific genes that were most common in this population are listed in Table 2. Half of the most
abundant genes identified at baseline were ESBLs. Healthy age-matched children from the same
areas were not significantly different from the malnourished children in overall ARG abundance
or specifically in carriage of ESBLs.
b-lactamase mediated antibiotic resistance is enriched after treatment with amoxicillin but

does not persist
Exposing a microbial community to antibiotics enriches for ARGs and antibiotic resistant
organisms. This is a central dogma of evolutionary medicine. This is visible in Figure 3.8, showing
ARG count over the course of the study divided by treatment group. By the end of the one-week
course of amoxicillin, subjects have a significantly greater abundance of b-lactamases (of all
classes) in their stool than those who received a placebo (Kruskal-Wallis, p<.0001). However, the
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response of an individual community to perturbation depends greatly on its state and stability at
the time of the exposure. By week 4, the enrichment is no longer visible at this resolution. The
hypothesis that AR enrichment would persist is not supported by the data measured here. Within
the narrower category of ESBLs, the same effect is seen where amoxicillin produces a significant
enrichment (Kruskal-Wallis, p<.0001) which then resolves (Figure 3.9).

3.3.4 Multiple mechanisms contribute to the benefit of amoxicillin on recovery
from SAM
Prophylactic amoxicillin prevents future incidence of diarrhea
Gains in diversity and maturation of the gut microbiome are good but still indirect metrics for the
impact of a medical intervention. Through the collections of survey data asking about symptoms
of disease at each study visit, we can observe the incidence of various symptoms during the twelve
weeks of follow-up (Figure 3.10). Within the various symptom categories, only diarrhea is
significantly different between treatment groups (t-test p<.05). This result echoes previous
findings in larger trials of antibiotics [337]. The potential mechanism for could be 1) elimination
of subclinical enteric pathogens present at baseline and/or 2) nutritional recovery may be
accompanied by improved resistance to new colonization and infection by diarrheal pathogens.
Sub-Saharan Africa contains a multitude of diarrheal pathogens [345]. Our bacterial taxonomic
annotations will not be able to quantify the burden of parasites Cryptosporidium and Cyclospora
or of rotavirus, but E. coli, Shigella, Salmonella, and Campylobacter are all indeed present and
dynamic within our study cohort. At the genus level, these taxa do not have an obvious correlation
with diarrhea in this dataset, but we plan to follow up on this by quantifying known diarrheal toxin
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Gene
TEM-79
TEM-12
TEM-92
tetW
TEM-57
TEM-192
TEM-60
TEM-26
TEM-28
TEM-196

Type
Class A beta-lactamase
Class A beta-lactamase
Class A beta-lactamase
Ribosomal protection
Class A beta-lactamase
Class A beta-lactamase
Class A beta-lactamase
Class A beta-lactamase
Class A beta-lactamase
Class A beta-lactamase

Phenotype
broad-spectrum
ESBL
ESBL
tetracycline resistance
broad-spectrum
unknown
ESBL
ESBL
ESBL
unknown

Genus
Escherichia
Klebsiella
Proteus
Bifidobacterium
Escherichia
Klebsiella
Providencia
Klebsiella
Escherichia
Shigella

Species
Average copies
coli
221.16
oxytoca
209.89
mirabilis
171.35
longum
145.04
coli
125.04
pneumoniae
120.83
stuartii
92.94
pneumoniae
87.08
coli
84.00
sonnei
69.38

Table 3.2. Top ten most abundant resistance genes found in baseline stool samples. ESBL=
extended-spectrum beta-lactamase.
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Figure 3.8. This box plot shows ARG count over the course of the study for all individuals and all
classes of b-lactamases in the CARD 2021 database. At week 1, there was a significant difference
in the total ARGs (Kruskal-Wallis, p<.0001), but it resolved by week 4 and every timepoint
thereafter (Kruskal-Wallis, p>.05).
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Figure 3.9. This visual shows only ESBL genes abundances throughout the study, as categorized
by the BLDB in 2018. As in the broader category of ß-lactamases, there is a significant enrichment
at week 1 (Kruskal-Wallis p<.0001) but at no other timepoint.
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Figure 3.10. Survey responses show the occurrence of symptoms in the 7 days prior to each study
visit. As the study invention can produce disturbance in the gut, the incidence of new-onset disease
symptoms is displayed from weeks 2 through 12. Diarrhea incidence is decreased in the
amoxicillin group after cessation of antibiotic therapy.
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genes (see Chapter 4). As was the case with C. difficile in Chapter 2, we may be limited by
resolution of sampling, as blooms of pathogens during diarrheal episodes can be ephemeral.
Metabolic genes and pathways associated with digestion of breast milk are significantly
reduced in amoxicillin treatment group compared with placebo
Healthy gut microbiomes transition through several community structures during early life [68],
the most dramatic of which is the transition occurs during weaning. An age-regressed
malnourished microbiome may well fail to make that transition. To test it, we can look at specific
genes for utilization of human milk oligosaccharide from the literature [346] Many of these human
milk oligosaccharide utilization genes are found in B. longum, which is a strong influence on the
age curve in our populations. Other families are associated with B. pseudocatenulatum and have
homologs in Enterococcus spp. To evaluate the association of breastfeeding associated genes with
treatment group and also directly with anthropometry with mixed effects linear regressions. Age
is of course very tightly correlated with the presence of these genes, but when age is controlled as
a random effect, the remaining signal from these oligosaccharide utilization genes is highly
predictive of the severity of SAM, as measured by age-independent anthropometric MUAC. The
results are provided Fig. 3.11-3.12 and Table 3.3. Even with the age association penalized, MUAC
is significantly associated with 41/134 oligosaccharide breakdown genes at p<.05 and with 24 of
them at p<.01 (Table 3.3). Meanwhile, amoxicillin is responsible for a significant and durable
reduction of F6C732, a glycoside/pentoside/hexuronide transporter found in Bifidobacterium
bifidum. These associations show strong support for the relationship between MUAC and
reduction in oligosaccharide utilization genes, as well as one potential mechanism for how
amoxicillin benefits recovery from SAM.
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Mid-upper arm circumference (cm)

Figure 3.11. This mixed effects linear regression shows a strong negative link between the relative
abundance of the gene family B7GNR2 with the SAM anthropometric of MUAC (cm) of all
samples. Age was entered as a random effect. B7GNR2 contains an ABC transporter permease
component assigned to Bifidobacterium longum. This gene was highlighted in the literature as
important to human milk oligosaccharide breakdown, which is expected to reduce as
anthropometry improves.
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Table 3.3 Significant associations between oligosaccharide utilization genes and MUAC,
computed by mixed effects linear regression through MaAsLin2 with age as a fixed effect.
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UniRef90_F6C732

Treatment group (0=placebo, 1=amoxicillin)

Figure 3.12. In this linear regression we that amoxicillin significantly reduces the abundance
F6C732, a glycoside/pentoside/hexuronide transporter found in Bifidobacterium bifidum. The data
shown here is for all subjects from weeks 0 through 12, indicating that the abundance of this gene
is not restored after cessation of antibiotic treatment.
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3.4 Discussion
The main arguments against the use of antibiotics in vulnerable populations are the loss of diversity
and selection for AR pathogens, which is especially worrisome when patients are
immunocompromised. Treating the gut microbiota of children with severe acute malnutrition
(SAM) therefore constitutes a special case combining all of the factors. In healthy children older
than 2 years, some adult-like stability and resilience to antibiotics should be characteristic.
Malnourished children however exhibit an age-regressed microbiome which is often lacking taxa
of a healthy child or adult [38]. Specifically, the gut microbiome of children with SAM is enriched
for Enterobacteriales and deficient in beneficial microbes such as Dorea spp. and
Faecalibacterium prausnitzii relative to healthy children living in the same geographical area [38].
Broad spectrum antibiotics could further deplete microbial defenses and inhibit the immune
system. The increase of potential pathogens on a background of poor microbiome and immune
health could be catastrophic leading to invasive AR bacterial infections.
The data to address the long-term concerns of antimicrobial treatment of SAM is accumulating in
placebo-controlled randomized trials of mass drug administration. Azithromycin and amoxicillin
have been trialed to improve all-cause mortality and SAM in sub-Saharan Africa [338, 347, 348].
Researchers analyzed the gut microbiome profiles of 600 preschool children (average age 32
months) randomized to receive a standard course of oral azithromycin or placebo every 6 months
for two years [349]. At the end of the two-year trial, no statistically significant differences were
present between groups in microbial richness, diversity, or phylum-level taxonomic composition.
This corroborates the research above that the gross architecture is not commonly affected by a
single course of antibiotics. When delving deeper into the analysis, the authors discovered a
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reduction in relative abundance of 35 species including Campylobacter spp., which can cause
diarrheal illnesses worldwide [349]. As a trade-off for decreased mortality, azithromycin increased
phenotypic AR of pneumococcus isolated from nares from children who completed the trial [350].
Similarly, ARGs encoding resistance to macrolides (of which azithromycin is a member), were
enriched in fecal metagenomes from azithromycin-exposed children. No other phenotypic
resistance in pneumococcus was significantly different between treatment groups, and there were
no differences in genotypic resistance determinants in whole fecal metagenomes [349, 350].
Amoxicillin is also routinely prescribed for uncomplicated SAM in sub-Saharan Africa; however,
similar concerns about the long-term consequences of this practice abound [351]. To address some
of these concerns for amoxicillin as described above, researchers determined rates of extended
ESBL prevalence in a randomized placebo-controlled trial of amoxicillin for SAM in Niger [338,
352]. Amoxicillin prophylaxis increased the percentage of Nigeran children who harbored ESBL
Enterobacteriaceae and were negative at baseline as determined by selective culturing [352]. This
result suggests either endogenous enrichment of below the limit of detection Enterobacteriaceae,
de novo acquisition of an ESBL Enterobacteriaceae, or in vivo horizontal gene transfer.
Additionally, untreated siblings of amoxicillin-treated children were more likely than placebocontrolled siblings to acquire an ESBL Enterobacteriaceae. Therefore, administration of
antibiotics can potentially affect long-term AR of specific genera and can lead to environmental
dissemination. However, given the repeated demonstration of their positive effect on childhood
health, we support this practice. Further research demonstrating the environmental impact of
increased AR in this population needs to be performed.
Outside of b-lactamases, the most common resistance genes were connected to tetracycline
resistance. Tetracycline is a favored drug for growth promotion in agriculture. This practice
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involves continuous subtherapeutic dosing of an antibiotic to food animals, and it results in
increased size and weight of both mammals and birds. The mechanism for the effect remains
unknown, but the results of this trial are highly relevant to that mystery as well. Most of the world’s
antibiotics by weight are destined for growth promotion and utilized under the circumstances that
are most likely to select for antibiotic resistance. Efforts to reserve medically important drugs for
human use remain incomplete. In the meantime, tetracycline resistance is rampant and not
unexpected even in children who have never been prescribed tetracycline.
The population in this study is exceptional in a number of ways. They are exceptionally vulnerable,
extremely sick, and very young. They are also enrolled in a nutritional therapy program that
radically changes their diet, body mass, and immune competence during a critical period in
microbiome development. The speed of microbiome maturation in this cohort can hardly be
duplicated by any other. For this reason, these results are not generalizable to any adult cohorts, to
other countries, or even to children without malnutrition in the same geographic region.
Precautions are being taken in writing and publicity to make ensure this data is not misinterpreted
or misused to justify widespread prophylactic use of antibiotics in other situations.
The cost and benefit calculation for these children requires consideration of both the benefits of
immediate recovery and the future risk of infections with AROs. The microbiome study presented
supported the findings that amoxicillin significantly aids nutritional recovery and it offers support
for two potential mechanisms. A single course of amoxicillin lowers future incidence diarrhea for
at least 3 months, which may be mediated by enteric pathogens. Amoxicillin may also help the gut
microbiota adapt to a more mature diet by reducing the abundance of oligosaccharide utilizations
genes and their hosts. The expected enrichment for antibiotic resistance and loss of bacterial
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diversity did occur but did not persist. Our findings indicate that resistance selection should not be
used as a reason to withhold potentially lifesaving treatment for these children.
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Chapter 4
Future directions
4.1 Introduction
As of yet, interventions into the human microbiome remain crude and untargeted. The unintended
consequences and side effects of the use of antimicrobials and fecal microbiome transplantation
are a severe shortcoming. Beneficial microbes die or may be displaced; overall gut microbial
community composition can shift in unexpected ways; post-intervention alpha diversity is highly
dependent on the initial composition and stability of the patient’s microbiome. What we contribute
with these works is a quantitative evaluation of which features of the microbiota are important and
relevant to C. difficile infection, childhood severe acute malnutrition, and carriage of AR genes
within the gut microbiota. Our studies offer prediction of the effects of these interventions on the
gut microbiota of similar population in future use. We directly and quantitatively address with the
frightening specter of antimicrobial resistance, showing circumstances where harm is minimized
and offering a method to reverse AR enrichment. Finally, our publicly available metagenomic and
culture isolate sequencing data adds to a valuable repository both for future hypothesis testing and
as a historic record in a changing environment.
The goal for the future of microbiome medicine is to have precise, targeted, reliably effective
interventions either to add microbiomes or to remove them. Defined probiotics are already
becoming better and more widely available, though efficacy remains extremely variable. Strides
have been made in using defined probiotics in primary prevention of C. difficile, with conflicting
results in CDI treatment [353]. Engraftment success rate of defined probiotics varies widely by
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product. The considerations for essentially infecting a sick person with a self-replicating organism
make the establishment of safety a slow and very necessary process. The next steps for
advancement of intervention for adding microbes are laid out below.

4.2 Fecal microbiota transplants in the context of antimicrobial resistance and
Clostridioides difficile infection
In chapter 2, we presented fecal microbiota transplantation as an avenue to reverse enrichment of
antibiotic resistance and even to eradicate AROs colonizing the gut microbiome. We did this in C.
difficile patients who had endured multiple courses of antibiotics without a cure. In doing so we
isolated, sequenced, and characterized 38 single and multidrug resistant bacterial isolates. By
tracking these isolates’ unique 16S rRNA gene in metagenomic sequences, we were able to
calculate their abundance over time within the patients’ gut microbiota and determine eradication
status to a high level of resolution. We contributed a valuable clinical trial sequencing dataset with
variable engraftment efficacy, as measured by weighted Unifrac distance from donor, and we
highlighted taxa associated with poorer or improved engraftment. We also showed that more
complete engraftments were more effective at reducing the count of ARGs in the recipients’
microbiomes.
This study was valuable in part because the microbiota therapeutic had a variable success rate.
However, it had important limitations in consistency of sampling, loss of Bacteroidetes from
repeated freeze thaws, and the lack of a placebo group to compare with the microbiome-based
therapeutic. Many of these flaws are addressed by the next clinical trial by Rebiotix, Inc.
Nevertheless, the ability of fecal microbiota transplantation to replace and possibly eradicate
AROs from the human gut microbiota could turn into an effective weapon against the global spread
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of dangerous resistance combinations. In order to get there, fecal transplants must become more
effective, better defined, and more reproducible. During the refinement process, the techniques
used in the paper can offer benchmarks for success and add to the publicly available sequencing
data. This manuscript is accepted for publication in Genome Medicine’s special microbiome issue
2021.

4.3 Prophylactic antibiotics in the context of childhood malnutrition
In Chapter 3, we answered the question of whether prophylactic antibiotics make a lasting
enrichment of antibiotic resistance genes in the microbiomes of these children. We found that the
is a significant enrichment of beta-lactamase genes as a direct result of the amoxicillin treatment,
as well as a reactionary increase in opportunistic Proteobacteria, but these effects resolve within 3
weeks of cessation of amoxicillin. Alpha-diversity of bacteria in the microbiome is not measurably
harmed. Other beneficial effects are lasting. Children treated with a prophylactic antibiotic have
better gains in anthropometry, a significantly decreased incidence of diarrhea that endured
throughout the rest of the study, and better graduation rates from nutritional therapy.
There are limitations on the design of this study. Randomized controlled trials are the strongest
form of evidence, but what was not random was the follow up care. If the children did very well
on the therapy and graduated (moved from severe acute malnutrition to moderate acute
malnutrition), their diet was changed to a less calorically intense food. This created a confounder
in the study, where the children with the best responses were no longer comparable to those who
did not. This was avoidable, as there are no health consequences from feeding them on the study
diet for the remainder of twelve weeks, and there is only a little more expense. On the other
extreme, a change in treatment plan was unavoidable if the status of the children deteriorated. In
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this study, children who failed to gain weight for two study visits in a row while on RUTF were
sent to inpatient treatment and observation. Continued data collection on these children would
have been optimal for the study design, despite more confounders from different treatment. Instead
having inpatient children considered lost to follow up made the original study outcome of mortality
almost impossible to measure accurately. And the healthy controls should have been collected at
the same time as the original samples. We remedied this by collecting them again as soon as
possible and collecting additional temporal control with severe acute malnutrition. It seems that
conditions in the region had not substantially altered the average bacterial composition of
malnourished children, so that particular study oversight was compensated for in the analysis.
These design flaws should not be fixed with another study of the same kind, because with the
additional data gathered here, randomizing children to receive placebo is unethical. Rather, in other
populations where there is still some question on the risk to benefit ratio for prophylactic
amoxicillin, these study flaws should not be repeated.
What still needs to be done? In terms of analysis, the only tasks left are modeling refinement and
tracking of diarrheal toxin genes. The initial surveys administered in the clinical trial included a
great deal of metadata, assessing variables that had to do with the environment and holdings of the
child’s household. The number of siblings, types of animals, and especially sanitation situation
may well leave signatures on the child’s microbiome. If offering extra chickens or port-a-potties
could make a difference, it is my responsibility to my research subjects to learn that from the data.
In addition to evaluating and incorporating these metadata variables, the current models
associating taxonomy and metabolic pathways with outcomes can also be optimized by changing
the normalization from counts per million read to simple log transform with the total read counts
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in negative binomial distribution. This retains the information pertaining to the size of the
uncertainty in the measurement.
As mentioned in Chapter 3, detecting diarrheal enteropathogens in a metagenome is not as simple
as taxonomic annotation. For example, the phylogeny of the Escherichia/Shigella/Salmonella
group of taxa is complicated and arbitrary. Functionally speaking, it contains many members that
are benign commensals, while others are deadly pathogens. Instead of using phylogeny to address
the mechanism by which amoxicillin prevents future incidence of diarrhea, I intend to compile a
list of genes that are essential to the pathogenesis of diarrhea, including but not limited to toxin
genes. I will use ShortBRED-identify to create protein markers based on these genes and then
quantify those markers in patient metagenomes.
After these last pieces of analysis, I will finalize the figures and finish the manuscript. It will be
formatted for submission to Microbiome at the end of March 2021.

4.4 Conclusions
The children who participated in the malnutrition project are mostly out of danger now, but there
are unfortunately many more who will present to clinics worldwide with severe acute malnutrition.
Climate change makes subsistence farming a very chancy occupation, as the land that has
supported the same crops for previous generations may suddenly get less rainfall or too much and
become barren. Expensive technology and selective crop breeding can increase the overall caloric
yield from an acre of land, but it cannot make people get better at sharing food, water, or wealth.
The global recession resulting from the COVID-19 pandemic will worsen the situation. In short,
the results of the global health work here on malnutrition will remain relevant for years to come.
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Antibiotics shape the ecology of the gut microbiome in profound ways capable of causing lasting
changes to both developing and mature microbiotas. The state of the microbiome, the duration,
route, and spectrum of antibiotic activity, other co-morbidities, diet, and post-antibiotic
environment all factor into the expected acute and chronic disruption and resilience from
perturbation [7, 13, 17, 48, 94, 135, 161, 349]. The most important issue for the microbiome field
in general is progression from understanding correlation to identifying causal molecular
mechanisms [32, 354, 355]. With the two original research projects and three other publications
presented here, I have made already made a substantial contribution to this field. With my career
ahead, I intend to make a substantial improvement in the lives and health of vulnerable populations
by studying the problems that afflict them and creating new and better solutions.
In the not too distant future, we will learn adapt and refine antibiotics and restoration therapies to
make use of their direct anti-pathogen benefit while simultaneously limiting collateral damage to
the microbiome and resistome [259, 356, 357]. It is naïve to assume that such direct agents will
not have their own collateral impacts on microbiome composition [357], but hopefully selective
agents will be less disruptive overall. The human gut microbiome is intimately linked to human
health and disease [7, 30, 358]. Only through carefully considering the impact of interventions on
the microbiome can we better treat diseases and improve human health.
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